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Abstract

MOSAICISM FOR TRISOMY 21: UTILITY OF ARRAY-BASED TECHNOLOGY
FOR ITS DETECTION AND ITS INFLUENCE ON TELOMERE LENGTH AND THE
FREQUENCY OF ACQUIRED CHROMOSOME ABNORMALITIES

By Chariyawan Charalsawadi, M.D., M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2011

Major Director: Jackson-Cook, Ph.D., FACMG
Professor, Pathology

The primary aim of this study was to determine the effectiveness of array-based
technology for detecting and quantifying the presence of mosaicism. This aim was
achieved by studying individuals having mosaicism for Down syndrome. SNP arrays
were performed on 13 samples from individuals with mosaicism for trisomy 21, 13
samples from individuals with normal chromosome 21complements (negative controls)
and 5 samples from individuals with full or partial trisomy 21 (positive controls). In
addition, BAC arrays were processed on 6 samples from individuals with mosaicism for
trisomy 21, 3 negative controls and 1 positive control. These studies have shown that

x

array-based technology is effective for detecting mosaicism that is present in 20% or
more cells with the results being consistent for both platforms. We also demonstrated the
strength of array-based technology to identify previously unrecognized chromosomal
mosaicism.
A second aim of this study was to gain insight regarding the effect that trisomy 21
has on telomere attrition and the frequency of chromosomal instability. This study
provides the first reported measure of both chromosome-specific telomere lengths and the
frequency of acquired chromosome abnormalities in trisomic cells and isogenic euploid
cells obtained from the same individuals. A chromosome-specific telomere length assay
was performed on lymphocytes obtained from 24 young individuals with mosaicism for
Down syndrome. While differences in overall telomere signal intensities were observed
between the euploid and trisomic cells within a person, strikingly similar profiles for
chromosome-specific telomere intensities were observed between the cell types within a
person. Analyses were also completed on lymphoblast samples obtained from 8 older
individuals with mosaicism for Down syndrome, including 5 individuals without
dementia and 3 individuals with dementia. In the older study subjects, a significant
inverse correlation was observed between telomere length and the frequency of
micronuclei, suggesting that telomeric shortening is leading to an increased frequency of
chromosomal instability, possibly through dicentric chromosome formation. However,
further studies of more individuals, especially additional analyses of older individuals,
are needed. These future studies may help to identify genomic regions of interest and
serve to inform investigators of potential candidate genes in the etiology of dementia.

Chapter 1

Introduction

Epidemiology and etiology of Down syndrome

Down syndrome (OMIM90685) is the best recognized and most common
chromosomal disorder seen in live born individuals, affecting 1/700-1/800 live births
(Sherman et al., 2007). Down syndrome is caused by a complete or partial triplication of
chromosome 21. This condition was first described in 1866 by John Langdon Down, but
the etiology of Down syndrome was not known until 1959, when Lejuene demonstrated
the presence of 3 copies of chromosome 21 in cells from individuals with Down
syndrome (Lejuene, 1959). It is known that the extra chromosome 21 originates from
nondisjunction during gametogenesis. Nondisjunction can occur during meiosis I (MI),
when the homologous chromosomes pairs fail to properly complete the reduction division
or during meiosis II (MII) when the chromatids fail to correctly separate. The use of
DNA polymorphic markers allowed geneticists to determine the parental and meiotic
origin of the nondisjunctional error that resulted in the presence of the extra chromosome
21 in people having Down syndrome. In approximately 90% of individuals with Down
syndrome, nondisjunction occurred in maternal meiosis, with the majority of these
(~75%) arising during MI. Paternal nondisjunction and mitotic malsegregation are far
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less prevalent, being seen in approximately 4 to 9% and 3 to 5% of cases, respectively
(Yoon et al., 1996; Sherman et al., 2007).

Progress has been made to identify associated factors that increase the risk for
chromosome 21 nondisjunction. By far, advanced maternal age is the most significant
risk factor (Janerich and Bracken 1986). The birth rate of infants having Down syndrome
is dramatically increased in women older than 35 years (1.8/1000 births) and older than
45 years (6.1/1000 births), when compared to the rates seen in 20- 24 years old women
(0.4/1000 births) (Yoon et al., 1996). This observation, in part, can be explained by: (1)
an accumulation of toxic effects/environmental insults/mitochondrial mutations during
the period of oocyte arrest; (2) a decrease in ovarian reserve/limited oocyte pool; (3)
hormonal imbalance; (4) impaired meiotic machinery; (5) altered meiotic
recombination/instability during chromosome segregation; and/ or (6) accumulation of
trisomy 21 oocytes due to preferential elimination of disomic oocytes (oocyte mosaicism
selection model) (Sherman et al., 2007; Hultén et al., 2010).

It is estimated that 95 % of individuals with Down syndrome have full or partial
trisomy 21. Of the remaining cases, approximately 2-4% are due to translocations
between chromosome 21 and another chromosome [e.g., t(14;21), t(21;22)] (Pangalos et
al., 1994; Devlin and Morrison, 2004; Shin et al., 2010). Approximately three fourths of
these unbalanced translocations are de novo mutations, with one fourth being present as a
result of malsegregation of a familial translocation (American Academy of Pediatrics,
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Committee on Genetics, 2001). The remaining proportion of people having Down
syndrome (1% to 4%) has mosaicism. Mosaicism is a condition in which an individual
has two or more genetically distinct cell lines that develop from a single zygote
(Thompson and Thompson, 2004). In the case of mosaicism for Down syndrome, an
individual has at least 2 populations of cells: one that has trisomy 21 (47,XX,+21 or
47,XY,+21) and one with euploid cells (46,XX or 46,XY).

Overview of Down syndrome clinical features

The phenotype of people having Down syndrome, which is thought to result from
the dosage imbalance of multiple genes, has been associated with more than 80 traits
(Epstein 1986), including a small brachycephalic head, epicanthal folds, upward slanting
palpebral fissures, Brushfield spots (speckling of iris), a small nose with a flat nasal
bridge, small mouth, hypoplasic teeth, small ears, short neck, nuchal skin folds, single
palmar creases, short metacarpals and phalanges, short fifth finger with clinodactyly, and
wide spacing between the first and second toes. Besides cognitive impairment, the
incidences of the most common clinical characteristics reported in people having Down
syndrome are summarized in Table 1 (Committee on Genetics, American Academy of
Pediatrics, 2001; Jones KL, 2005). Although individuals with Down syndrome are
predisposed to develop childhood leukemia, epidemiologic studies revealed that
individuals with Down syndrome have a lower incidence of developing solid tumors,
especially breast cancer, when compare to the general population (Hasle et al., 2000).
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Down syndrome has also been associated with primary gonadal deficiency, which
contributes to their fertility reduction. Although, a number of females with Down
syndrome have been reported to produce offspring (approximately 50% having a normal
chromosomal complement and 50% having Down syndrome) (Sheridan et al., 1989),
nearly all males with Down syndrome are infertile. Only a few case reports of males with
non-mosaic Down syndrome have been reported to have offspring. Paternity studies
completed for these cases confirmed that the men having Down syndrome were the
biological fathers (Bobrow et al., 1992; Zuhlke et al., 1994; Pradhan et al., 2006).

Cognitive impairment in people having Down syndrome is variable, ranging from
mild (IQ: 50-70) to moderate (IQ: 35-50), and occasionally severe (IQ: 20-35)
(Committee on Genetics, American Academy of Pediatrics, 2001; Jones KL, 2005; Tarek
2005). The presence of visual and hearing impairments may further limit overall
cognitive function, and language and psychosocial skill development. In addition,
unrecognized thyroid dysfunction may compromise cognitive function. The development
of seizures may also deteriorate cognitive function (Lott and Dierssen, 2010; Chen et al.,
2011). An area of particular compromise for individuals with Down syndrome appears in
their auditory short-term memory skills, which has been conjectured to cause expressive
language skill impairment (Chapman and Hesketh, 2001).

4

Table 1: Clinical characteristics of individuals with Down syndrome

Characteristics

Percentage

Hypotonia

80%

Congenital heart defects, including endocardial cushion defect or atrioventricular canal

40-58%

defect, ventricular septal defect, patent ductus arteriosus, atrial septal defect, mitral valve
prolapse with or without tricuspid valve prolapse and aortic regurgitation
Hearing loss, including conductive, mixed, or sensorineural hearing loss

70-90%

Otitis media

50-70%

Eye diseases, including
-

Congenital cataracts

15%

-

Acquired cataracts in adults

30-60%

-

Severe refractive errors (mostly myopia)

50%

Obstructive sleep apnea

50-75%

Thyroid disease

15%

Seizures

<9%

Gastrointestinal tract anomalies, including
-

Duodenal atresia

12%

-

Hirschsprung disease

<1%

Spine anomalies, including
-

Incomplete fusion of vertebral arches of lower spine

37%

-

Atlantoaxial instability

12%

Hip dislocation

6%

Increased risk of leukemia and leukemoid reaction

<1%
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Down syndrome: a syndrome of premature aging
Approximately 75% of concepti with trisomy 21 die prenatally. Approximately
85% of live born infants survive to age 1 year and 50% are expected to live longer than
age 50 years (Tarek 2005). Congenital heart disease is the major factor that determines
early survival. In addition, frequent infections that are presumably due to impaired
immune responses and leukemia also contribute to high mortality (Chen et al., 2011).
However, as a result of improvements in medical care, the survival of individuals with
Down syndrome has markedly increased. Life expectancy estimates for people with
Down syndrome have increased from 9 years old in 1929 to 60 years in 2000 (Bittles and
Glasson, 2004). Age-related disorders in individuals with Down syndrome begin earlier
than in the general population. Several precocious aging characteristics have been
reported in 30 to 40 year-old individuals with Down syndrome, including acquired
cataracts, alopecia, premature graying of hair, age-related hearing loss, skin atrophy,
hypogonadism, early onset menopause, degenerative vascular disease senile dementia
and an increased prevalence of Alzheimer disease (Potter, 1991; reviewed in Esbensen
2010).

How people with Down syndrome age prematurely is not known. The DNA
damage theory had been proposed to explain precocious aging in Down syndrome. This
theory, which postulates that aging is a consequence of accumulation of unrepaired DNA
damage, is supported by the finding of increased sensitivity to the DNA-damaging agents
and impaired cellular reaction to DNA damage in individuals with Down syndrome
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(Morawiec et al., 2008). In addition, DNA damage has been found to be increased in
individuals with Down syndrome in relation to control individuals (Maluf and Erdtmann,
2001). An alternative explanation that has been suggested to explain the precocious aging
of people with Down syndrome focuses on free-radical metabolism. One of the key
enzymes involved in free-radical metabolism is superoxide dismutase (SOD-1), which is
encoded by the SOD-1 gene on chromosome 21. This explanation is supported by the
finding that cells from individuals with Down syndrome have a decreased ability to repair
oxidative damage to mitochondrial DNA compared to age-matched controls (Druzhyna et
al., 1998).

A relationship between the progression of aging and telomere length has been
shown in chromosomally normal individuals from the general population (Wright and
Shay, 1995; Fredrich et al., 2000; Stewart and Weinberg, 2006; Mayer, et al., 2006; Guan
et al., 2007). A telomere is a specialized structure at the end of a chromosome that plays a
role in ensuring chromosomal integrity. Several observations, both in vitro and in vivo,
have shown that telomeres act as a mitotic clock; with the shortening of telomeres that
occur with every cell division eventually causing cellular senescence and cell death
(Herbert et al., 1999; Sherr and DePinho, 2000; Campisi, et al., 2001). Telomere
shortening and a concomitant increase in genomic instability have also been described in
older individuals having Down syndrome (Vaziri et al., 1993; Maluf and Erdtmann,
2001).
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Given that individuals with Down syndrome exhibit similar neuropathological
features to those observed in individuals acquiring Alzheimer disease, it has been
speculated that the neurodegenerative courses in Alzheimer disease and Down syndrome
are closely related. Alzheimer disease is the most common form of dementia in the
elderly. It is characterized by progressive dementia associated with several
neuropathologic findings, including cerebral cortical atrophy and the accumulation of
intracellular neurofibrillary tangles harboring hyperphosphorylated tau and extracellular
β-amyloid plaques (Kimura et al., 2007). In the general population, early-onset
Alzheimer disease symptoms usually start before age 60 to 65 years and often before age
55 years, while the prevalence of clinical dementia/Alzheimer disease in individuals with
Down syndrome present at an earlier age (the fourth and fifth decades of life) (Holland et
al., 2000). However, neuropathologic characteristics consistent with Alzheimer disease
have been observed (at autopsy) in the brains of individuals with Down syndrome as
early as 30 years of age (Mann and Esiri 1989) and in the brains of all individuals with
Down syndrome over the age of 40 years (Wisniewski et al., 1985). The diagnosis of
Alzheimer disease in individuals with Down syndrome is complicated by their preexisting developmental delay (Brugge et al., 1994). In addition, individuals with Down
syndrome have limitations in motor, language, communication and intellectual abilities;
therefore the detection of subtle changes in these functioning areas requires sensitive
assessment scales. Furthermore, individuals with Down syndrome may also have other
health problems associated with aging (e.g., hypothyroidism and depression) that may
mimic or mask the presence of Alzheimer disease (Bush and Beail, 2004).
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Alzheimer disease is a genetically heterogeneous condition. Most forms of
familial Alzheimer disease (AD1) are caused by a mutation in the gene encoding the
amyloid precursor protein (APP; OMIM 104760) on chromosome band 21q21.2
(http://www.ncbi.nlm.nih.gov/omim/104300). In these patients, the cerebral deposition of
β-amyloid, the main component of amyloid plaques, has been associated with triplication
of the APP gene (Hardy, 1992; Mann, 2004). These amyloid plaques are thought to lead
to neuronal death and subsequently progressive signs and symptoms of Alzhemer disease.
In addition to the APP gene, other genes on chromosome 21 that may be involved in the
pathogenesis of Alzheimer disease include, but are not limited to, the superoxide
dismutase (SOD-1) gene and the dual-specificity tyrosine-(Y)-phosphorylation regulated
kinase 1A (DYRK1A). It has been speculated that oxidative stress may be relevant to
neurodegeneration in people with Down syndrome (Percy et al., 1990), as SOD-1 is
located on chromosome 21q22.1 and the activity of SOD-1 is elevated in their blood cells
(De la Torre et al., 1996). SOD-1 is an enzyme that converts oxygen radicals to hydrogen
peroxide and water. In people having Down syndrome SOD-1 activity is increased due to
triplication of chromosome 21, with this increase being disproportionate to the activity of
the downstream enzymes responsible for removal of hydrogen peroxide (e.g., glutathione
peroxidase)(Brooksbank and Balazs, 1984; Dyer and Sinclair, 1998). This imbalance is
thought to result in accumulations of hydrogen peroxide in the brain, causing neuronal
damage which, in turn, results in the particularly rapid neurodegeneration with age that is
similar to that seen in people having Alzheimer disease (De Haan et al., 1997). The
DYRK1A, which is a candidate gene responsible for learning and memory deficit in
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individuals with Down syndrome, has recently been demonstrated to be involved in the
development of Alzheimer disease. The DYRK1A gene was found to be over expressed in
the brains of individuals with Alzheimer disease with and without Down syndrome.
Furthermore, an extra copy of the DYRK1 gene has been observed to lead to an increased
expression and activity of DYRK1 kinase enzyme and has resulted in increased tau
phosphorylation (Kimura et al., 2007; Liu et al, 2008; Wegiel et al., 2011).

Another biological factor that has been associated with the development of
Alzheimer disease status in the general population is telomere attrition. The relationship
between telomere shortening and Alzheimer disease has also been studied in individuals
with Down syndrome. Jenkins et al. (2006) observed increased telomere shortening in
adults with Down syndrome having dementia compared to age-matched individuals with
Down syndrome who did not have dementia (Jenkins et al., 2006; Jenkins et al., 2008).
Given that early clinical symptoms of Alzheimer disease can be very difficult to
recognize, Jenkins et al. (2010) proposed that telomere shortening, especially for
chromosome 21, may be used as a biomarker for early detection of Alzheimer disease in
the Down syndrome population and could allow for benefits to be realized from early
intervention before damage to the central nervous system occurred.

The biological basis for the role of the telomere in Alzheimer disease
development has been proposed to arise from a decreased efficiency in DNA repair
processes, leading to the accumulation of mutations which, in turn, result in an increased
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level of DNA damage. Aviv and Aviv (1998) proposed that erosion of the telomere leads
to chromosomal instability. At the chromosomal level, telomeric shortening may give rise
to acentric chromosome fragments which would not be subsequently pulled toward the
daughter nuclei at the time of nuclear division, being left in the cytoplasm as micronuclei
(MN)(de Lange, 2005). In addition, MN may originate from whole chromosome lagging
(reviewed in Fenech, 2007). A strong correlation between chromosomal aberrations and
MN formation has been shown (Jones, et al., 1994). It has also been shown that MN
frequency increases with age (Bolognesi, et al., 1999; Bonassi, et al.,2001); toxic
substance exposure [e.g., lead (Kasuba, et al., 2010) and arsenic (Colognato, et al.,
2007)]; and radiation exposure (Cho, et al., 2009; Banerjee et al., 2008);
neurodegenerative diseases [e.g., Alzheimer disease (Migliore et al., 1997; Petrozzi et al.,
2002), and Parkinson disease (Petrozzi et al., 2002; Migliore et al., 2002)]; obesity and
metabolic syndromes (Andreassi et al., 2011); and cancer (Duffaud, et al., 1997; Bonassi
et al.,2007; Milosević-Djordjević et al., 2010).

One of the methods for studying acquired chromosomal changes is through use of
the cytokinesis-blocked micronucleus (CBMN) assay, which has been adopted by many
laboratories. The CBMN assay, which was introduced by Fenech and Morley (1985), is a
one of the most widely-used methods for measuring the frequency of MN. This cytome
assay also allows for measuring other cytological structures that are indicative of
chromosomal damage including nuclear buds (NBUD), which are thought to be a
biomarker of eliminated amplified DNA and/or DNA repair complexes and
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nucleoplasmic bridges (NPB), which serve as a biomarker of DNA misrepaired and/or
telomere end-fusions. Interestingly, an increase in spontaneous MN frequency with age
has been reported in buccal cells from individuals with Down syndrome (Thomas et al,
2008; Ferreira et al, 2009)., but there is a paucity of reports of MN frequencies in
lymphocytes of people having trisomy 21.

Mosaicism for Down syndrome
The reported incidence of mosaicism for trisomy 21 may represent only a subset
of individuals having mosaicism. One of the main reasons for this bias is that
conventional cytogenetic technologies are limited in their ability to detect mosaicism,
especially for cases having low levels of trisomic cell lines. In addition, the phenotypic
appearance of individuals with low level mosaicism is often subtle, leading to a lack of
recognition of the condition based on a physical examination. Therefore, the true
prevalence of mosaicism for Down syndrome in the general population could be
underestimated. It has been postulated that whenever a larger number of cells are studied,
using fluorescent in situ hybridization (FISH) methodologies, trisomy 21 mosaicism may
be surprisingly common in the general population (Hultén et al., 2010).

Trisomy 21 mosaicism can originate in two ways:
1) Somatic origin. After fertilization involving euploid gametes, a normal zygote
with 46 chromosomes undergoes a mitotic nondisjunctional event (or anaphase lag)
involving a chromosome 21 to result in a cell with 3 copies of chromosome 21. The cell
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with three copies of chromosome 21 may continue to proliferate, giving rise to the
trisomic cell line. However, the reciprocal daughter cell having only one copy of the
chromosome is more often at a selective growth disadvantage and usually will not
continue to reproduce (Gardner & Sutherland, 1996) (Figure 1a).
2) Meiotic origin. A meiotic error of chromosome 21 occurs during oogenesis or
spermatogenesis which, following fertilization, results in an abnormal fertilized egg
having 47 chromosomes (i.e., trisomic 21 zygote). A subsequent mitotic loss of the extra
copy of chromosome 21 in one or more cells during embryogenesis, through a process
called trisomy rescue, results in the presence of a normal cell line (Figure 1b).
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1)
(a) Somatic
Origin

(b) Meiotic Origin

Figure 1: Origin of trisomy 21 mosaicism. (a) Somatic origin. After fertilization of euploid gametes, a normal zygote
with 46 chromosomes undergoes a mitotic nondisjunctional event, resulting in a cell with 3 copies of chromosome 21
(black) and a cell with single copy of chromosome 21 (gray). The cell with one copy of chromosome 21 tends to have
proliferative disadvantage, while the cell with 3 copies of chromosome 21 may continue to proliferate and gives rise to
a mosaic zygote containing trisomy 21 cells and normal cell (white). (b) Meiotic origin. Following fertilization of a
normal gamete with a gamete containing 2 copies of chromosome 21 due to a meiotic error, a trisomic zygote is
formed. A subsequent mitotic loss of the extra copy of chromosome 21 in one or more cells occurs during
embryogenesis, giving rise to the mosaicism.
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The clinical manifestations of mosaicism for Down syndrome are highly variable,
ranging from a phenotype comparable to that of individuals having “complete” trisomy
21 to a nearly normal phenotype. These phenotypic differences are thought to be due to
variable numbers of trisomic cells in different people, as well as variation from tissue to
tissue within a person (Papavassiliou, et al. 2009). The proportion of trisomic cells
present may be influenced by the viability of trisomic cells in the specific cell lineages.
Mosaicism originating from a meiotic error or a mitotic error that gives rise to a trisomic
cell line that is present during early stages of embryogenesis, such as blastulation, may
lead to generalized mosaicism in which most tissues are affected. An error that occurs at
a later embryonic stage, such as during gastrulation, in which the 3 major cell lineages
(i.e., ectoderm, mesoderm and endoderm) are being established, may affect a smaller
proportion of the cells or result in mosaicism that is confined to a certain tissue(s). The
type of cells that are affected may also determine the phenotypic outcome. If the genetic
information on chromosome 21 is essential for the development of the affected tissue(s),
it could either impair the overall function of that tissue(s) or lead to a selective
disadvantage of the trisomic cells. Herein, certain mechanisms involved in cell selection
help prevent the abnormal trisomic cells from reproducing, which in turn minimize or
eliminate the effects of the genetic imbalances resulting from trisomy for chromosome
21.

As noted above, individuals having a higher frequency of trisomy 21 cells tend to
have more clinical traits than those who have lower proportions of trisomic cells
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(Papavassiliou, et al. 2009). Correlations have also been observed between phenotypic
findings and level of trisomy 21 cells in different tissues. For example, IQ scores have
been negatively correlated to the proportion of trisomic buccal cells, while the presence
of congenital heart disease has been positively correlated to the proportion of trisomic
lymphocytes (Papavassiliou, et al. 2009). This observation could be explained by the
underlying embryonic origin of these tissues since both buccal cells and brain cells are
ectodermal in origin and both lymphocytes and cardiac muscle cells are derived from the
mesoderm. Children with mosaicism for Down syndrome have been shown to have a
significantly lower prevalence of major congenital heart disease (36.4%) than children
with non-mosaic Down syndrome (49.3%) (Shin et al., 2010). The types of congenital
heart disease were also found to be different between individuals with mosaicism and
non-mosaic or “complete” trisomy 21. The atrioventricular canal defect was found to be
more common in the individuals having “complete” trisomy 21, whereas the less severe
anomaly, atrial septal defect, was more prevalent in mosaic individuals (Papavassiliou et
al., 2009).

Age-related changes leading to the acquisition of “mosaicism” have been
documented in individuals having “complete” trisomy 21 (Jacob et al., 1961; Percy, et al.,
1993; Jenkins, et al., 1997). The causes of chromosome 21 loss with advanced aging are
not clear, but could be due to: (1) an increase in abnormal cell division (e.g., higher
frequency of mitotic nondisjunction) with increasing age leading to loss of a chromosome
21; and (2) cell-line selection in the case of individuals having constitutional mosaicism
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(e.g., diploid cells have proliferative advantage). Percy, et al. (1993), who observed a
significantly increased proportion of diploid cells in older individuals having Down
syndrome, hypothesized that the age-related loss of chromosome 21 could be related to
the clinical expression of Alzheimer disease in these individuals, as well as individuals
from the general population.

Diagnostic tools in cytogenetics and their abilities to detect mosaicism
While consistent constitutional mosaicism is a rare event, more recent studies
have suggested that acquired chromosomal mosaicism may be a common event in the
very early development of embryos (Vorsanova, 2005). Based on these new observations
of “global” mosaicism, Iourov (2008) has speculated that residual somatic mosaicism
may be a contributive factor affecting phenotypic expression variations in several agerelated diseases, including, but not limited to cancer (Albertson and Pinkel, 2003;
Albertson and Pinkel, 2005).

Chromosomal mosaicism can be detected by conventional Giemsa banding
(GTG-banding) karyotype analysis, which is currently the standard diagnostic test used in
clinical cytogenetic laboratories. This test allows for the whole genome identification of
balanced and unbalanced numerical and structural chromosome aberrations. However,
subtle cytogenetic aberrations may not be detected. At the level of routinely prepared
metaphase chromosomes, which typically contain ~400-500 bands per haploid genome,
deletions and duplications that are smaller than 5-10 Mb may not be reliably detected.
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Deletions and duplications of 3-5 Mb can be detected by high resolution G-banding of
prophase or early metaphase chromosomes, which contain ~800-1000 bands per haploid
genome. However, this method, is not routinely used due to the fact that it is very labor
intensive (Shaffer and Bejjani, 2004).

In the late 1980s and early 1990s, molecular genetics techniques, in particular,
fluorescent in situ hybridization (FISH) (Pinkel et al., 1986), were implemented in
clinical cytogenetic laboratories. FISH is currently one of the most widely used
diagnostic molecular cytogenetic methods and has become an essential adjuvant assay.
FISH is based on the hybridization of complementary fluorescent-labeled probe(s) to
target DNA sequences. It can be performed on both metaphase chromosomes and
interphase nuclei and can allow for the detection of submicroscopic rearrangements at the
resolution of approximately 80-200 kb (Shaffer et al., 2001). A large number of probes
are available for different diagnosis purposes (summarized in Table 2).
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Table 2: Variations of commonly used FISH probes
Type of FISH probe
Chromosome enumeration
probes (centromeric probes)

Diagnosis purpose

Reference

Detection of aneuploidy (e.g.,

Klinger et al., 1992

trisomy 21, triomy 18 and
trisomy 13)

Locus-specific probes

Detection of particular

Kallioniemi et al., 1992

microdeletions or duplications
(e.g., RB1 locus)
Dual color fusion probes

Detection of gene

Dewald et al., 1993; Bentz et al., 1994

rearrangements in cancer (e.g.
BCR/ABL)
Dual color break apart
probes

Detection of gene

Einerson, et al., 2006

rearrangements in cancer (e.g.
IGH/MYC)

Telomeric probes

Detection of cryptic deletions

NIH and Institute of Molecular

and translocations in the

Medicine Collaboration, 1996

telomeric regions
Multicolor FISH (cenMFISH) and/or spectral

Characterization of a multitude

Nietzel et al., 2001; Schrock et al., 1996;

of alterations

Schrock et al., 1997; Speicher et al.,

karyotyping (SKY)

1996; Chudoba, et al., 1999
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The use of FISH methods for scoring targeted chromosomal regions in interphase
nuclei, in particular, allows for assessments of chromosome copy numbers from large cell
populations, making FISH a time efficient and sensitive method. Although FISH allows
for higher resolution for detecting small genomic abnormalities than conventional Gbanding, this approach is limited in that it lacks whole genome coverage and requires a
priori knowledge (e.g., distinctive dysmorphic features for genetic syndromes or
suspected diagnosis for hematologic malignancies) to identify the test(s) that will be of
clinical value. While 24-color FISH methods (M-FISH or SKY) provide whole genome
coverage, these methods have limitations akin to those noted for conventional GTGbanding, in that their ability to detect small deletions is limited. In addition, they do not
allow for the recognition of intrachromosomal aberrations that do not result in a change
in chromosome number or mortphology and are most effectively applied only for the
interpretation of metaphase chromosome preparations (not interphase nuclei).

Comparative genomic hybridization (CGH), which was developed by
Kallioniemi et al. (1992), is an alternative FISH-based methodology that uses DNA from
the specimen being evaluated as the “probe” to determine chromosomal alterations.
Briefly, in this method, two genomic DNA samples (test and reference) are differentially
labeled with distinct fluorochromes and then competitively hybridized onto normal
metaphase chromosomes. The ratio of the two fluorochromes present on the
chromosomes are then quantified, using specialized computer software, to determine
imbalances (gains and/or losses) in DNA sequences across the genome. However, since
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conventional CGH is carried out on metaphase chromosomes, its resolution is limited to
~3-10 Mb (Pinkel et al., 1998). In addition, this method cannot detect balanced
chromosome rearrangements, such as balanced reciprocal or Robertsonian translocations
and inversions. Recently, genomic microarrays were developed for CGH applications.
Array CGH shares the same principles as conventional CGH, except metaphase
chromosomes have been replaced with DNA fragments (e.g., bacterial artificial
chromosomes [BACs], oligonucleotides and/or PCR-generated sequences) as targets for
the hybridization (Solinas-Toldo et al., 1997; Pinkel et al., 1998; Snijders et al., 2001;
Pinkel and Albertson, 2001; Fiegler et al., 2003a; Fiegler et al., 2003b Veltman et al.,
2003; Vissers et al., 2003; Albertson and Pinkel, 2003).

Currently there are 2 distinct types of microarray platforms: 1) single channel
platform, in which test and reference samples are hybridized onto different matrices and
2) two-channel platform, in which both test and reference samples are co-hybridized on
the same matrix (i.e., array CGH). Fundamentally, they operate by the same principle.
For array CGH platforms, DNA from test and reference samples are labeled with
different fluorophores and then competitively hybridized to a microarray including
hundreds to millions DNA probes that are complementary to targeted genomic regions.
The relative fluorescence intensities of the test DNA to the reference DNA is then
calculated, with this value typically being transformed to a log2 ratio for assessment. A
log2 ratio represents a fold change measurement of input signals for the test and reference
samples and therefore reflects the copy number change.
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The resolution of array CGH is limited by the size of the target sequences, as well
as the distance between the BACs or oligos spotted onto the array. Recently, high density
single nucleotide polymorphism (SNP) genotyping arrays, which were originally
designed for whole genome association studies, have gained popularity for cytogenetic
testing. This technology relies on hybridization of one sample to an array, with the results
of that hybridization being compared in silico to a database of standard reference DNA to
determine the presence of imbalances. SNP arrays have the advantage that they allow for
the detection of long contiguous stretches of homozygosity (LCSH), in addition to
recognizing copy number gains and losses. Thus, both imbalances and LCSH, the latter
of which may be indicative of isodisomic uniparental disomy (UPD), identity by descent,
or loss of heterozygosity (LOH), can be detected in a single experiment.

The clinical implementation of array-based technology has revolutionized
cytogenetic diagnostic testing, being recently recommended as a first-tier assessment test
for chromosomal imbalances (Miller et al., 2010). Array-based technologies have been
developed for the analysis of clinically significant regions (targeted array) (Cheung et al.,
2007) and the entire genome (whole genome array) (Snijders et al., 2001; Veltman et al.,
2003; Vissers et al., 2003). The current limitations of array CGH include the inability to
detect polyploidy and balanced chromosome rearrangements. Copy number alterations of
unknown significance can also be problematic since significant knowledge regarding
copy number variations (CNVs) throughout the genome and their exact roles are yet to be
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determined. At this time, it is recommended that abnormalities or variations that are not
recognized as variable regions in genome data bases, have reflex testing of parental
samples to determine the clinical relevance, if any, of these findings (Manning and
Hudgins 2007).

All of the cytogenetic tools described above can be used for mosaicism detection
(Table 3). In general, when 20, 30 or 50 cells are evaluated without detection of
mosaicism, the lowest level of mosaicism excluded with 95% confidence is 14, 10 and
6%, respectively (Hook, 1977). However, mosaicism that affects a small chromosomal
region (i.e., less than 3Mb) or that is present in leukocytes other than T-cells may escape
detection using conventional G-banding. Interphase FISH is a sensitive method for
detecting low level mosaicism, allowing for the recognition of cell lines present in as low
as 1% of the cell population (Dewald G, et al., 1998). However, this technology is limited
because relatively few loci can be interrogated in a single experiment. Therefore, without
prior knowledge of the chromosome or chromosomal region affected, mosaicism might
be missed.
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Table 3: Comparison of molecular cytogenetic techniques used for mosaicism detection
Cytogenetic techniques

Level of mosaicism detection

Chromosome G-banding

6-10% (Barch et al., 1997)

FISH

<1 % (Dewald et al., 1998)

Multiplex ligation-independent probe amplification

14% (Van Opstal et al., 2009)

(MLPA)
Quantitative fluorescent polymerase chain reaction

10% (reviewed in Hulten et al., 2003)

(QF-PCR)
Conventional CGH

16% (Lestou et al. 1999)

Array CGH

5-20% (Ballif et al., 2006; Cheung et al., 2007;
Conlin et al., 2010)
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Since microarray-based technology is increasingly being used in clinical
diagnosis, an evaluation of its sensitivity for mosaicism detection is essential. The ability
of array-based technology to detect the presence of multiple cell populations has also
been shown through studies of in vitro contrived cellular admixture, constitutional
mosaicism and acquired chromosome abnormalities in cancers (Table 4). Based on their
in vitro contrived cellular admixture studies, Ballif et al. (2006) and Scott et al (2010)
concluded that mosaicism levels of 20% to 40% could be consistently detected using
array technology, but that values of 10% or less could not be unequivocally distinguished
from non-mosaic cases. Using a SNP array, Conlin et al., 2010 reported detecting
mosaicism for complements present is a low as 5% of cells. In this study, mosaicism was
identified from a logR ratio and B allele frequency (BAF). The latter was also suggested
to be useful for identifying mechanisms of mosaicism occurrence (i.e., origin of
segregation error). However, when the proportion of abnormal cells was very low (e.g., at
5-10%), distinction between meiosis and mitosis origins were problematic.
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Table 4: Summary of previous studies on mosaicism using array-based technologies

% Mosaicism (gain/loss)
Manufacturer
array

Array
type

Specimen
type

# mosaic cases
studied

Chromosome(s)
evaluated

FISH/GTG

Array (% minimum detected)

Reference

GenoSensor
Array 300

BAC/PAC (CGH)

frozen fetal
lung tissue

1

i(18q)

17%(GTG),21%(FISH)

NA

Le Caignec et al.,
2005

In house

BAC (CGH)

PB

1

monosomy 7

8%

5%

Manten et al., 2006

Signature Chip

BAC (CGH)

PB

18a
5b

varya
trisomy21b

10-50%(uncultured cells)
3-77% (cultured cells)
10-50% (artificial)

10% (subtle)
20% (clear)

Ballif et al., 2006

In house
targeted

BAC (CGH)

PB

12

vary

1.5-31%(uncultured cells)
2-33%(cultured cells)

7.0%

Cheung et al., 2007

44k Agilent

Oligo (CGH)

PB

8

trisomy 13,
trisomy 21

10.3-77.1%(QF-PCR)

10-12.3%

Hoang et al., 2007

In house
targeted

BAC (CGH)

PB

5

trisomy 14

9.5-42% (uncultured cells)
2-15% (cultured cells)

12.4%

Shinawi et al., 2008

GeneChip
Mapping 250K
Nsp Array

SNP

? PB or BM

3

trisomy 21

25-50%

NA

Gondek et al, 2008

In house

BAC (CGH)

PB

48

vary

NA

10%

Neill et al., 2010

105K Agilent

Oligo (CGH)

PB

48 a
4b

vary a
trisomy 21b

10-30% b

21% a
10%-20% (subtle) b
30% (clear) b

Neill et al., 2010

Affymetrix 50K
Xba Array

SNP

fibroblast

6

trisomy 8

0-100%

10% (subtle)
20% (clear)

Cross et al., 2007

Affymetrix 6.0
Array

SNP

PB

1

trisomy 21

8-13%

NA

Leon et al., 2010
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Table 4: Summary of previous studies on mosaicism using array-based technologies (continued)

% Mosaicism (gain/loss) detected
Manufacturer
array

Array
type

Specimen
type

# mosaic cases
studied

Chromosome(s)
evaluated

44K Agilent

Oligo (CGH)

PB, POC,
CV

7a
28 b

Illumina
HumanHap550
Bead Chip (V3)

SNP

PB, skin

Illumina
Quad610
genotyping
Bead Chip

SNP

Illumina
HumanHap
1M Bead Chip
244K Agilent

FISH/GTG

Array

Reference

vary a
[trisomy 21,
monosomy X,
dup(3), del(15)] b

17-94% a
0-100%b

10% whole chromosome
20-30% segmental aneuploidy

Scott et al., 2010

21

vary

2-100%

5%

Conlin et al., 2010

UC

1

t(5;12) [del(5)
and dup (12)]

87% (AF), 13-43%
(postmortem tissues, various
organs)

20% (UC)

Veenma et al., 2010

SNP

PB

34

Vary

NA

10% (UPD), 18% (del), 23%
(dup and/or trisomy)

Rodríguez-Santiago
et al., 2010

Oligo (CGH)

PB, BM

3

del(20), del(13),
del(7) and dup(7)

11.5-14.5%

11.9%

Valli et al., 2011

a

real specimen, b artificial specimen (a mixture of specimens or DNA from abnormal and normal cases), PB = peripheral blood, BM = bone marrow,
UC = umbilical cord blood, POC = product of conceptus, CVS = chorionic villi, AF = amniotic fluid
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Rationale for study

This review has shown the clinical relevance of constitutional (and acquired)
mosaicism and highlighted the strengths and weaknesses of diagnostic methodologies
used for mosaicism detection. While exciting results of case reports suggest that array
technology can be useful for detecting constitutional mosaicism in patients presenting
with clinical findings, to date, no systematic study of individuals having carefully
documented proportions of mosaicism has been completed. Therefore, the first aim of
this study was to determine the effectiveness of array-based technology for detecting
levels of mosaicism. This aim was achieved by studying individuals having mosaicism
for Down syndrome for whom the proportion of trisomic cells had been previously well
documented using FISH methodology. The data obtained from this facet of this study
allowed for testing the following hypotheses:

1) The relative fluorescence intensities obtained from microarray data, measured by
the smoothed mean of log2 ratios of all probes across chromosome 21, are
positively correlated with percentage of trisomic cells determined to be present in
study samples using FISH methodology.

2) Array-based technology allows for the detection of a trisomic cell population that
is present in 20% or more cells.
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A second aim of this study was to gain insight on the effect that trisomy 21 has on
telomere attrition. Given that people having Down syndrome show signs of premature
aging and are at risk for developing Alzheimer disease, studies of their cells may provide
knowledge regarding the relationship between telomere shortening, genomic instability,
aging and Alzheimer disease. Studies of isogenic trisomic and normal cells from
individuals having mosaicism for trisomy 21 provide a unique opportunity to evaluate
effects of trisomy 21 on a trait without confounding influences attributable to differences
due to age, genomic complement and environment exposure. This study provides the first
reported measure of both chromosome-specific telomere lengths and the frequency of
acquired chromosome abnormalities in trisomic cells and isogenic euploid cells obtained
from the same individuals. The data obtained from this study allowed for testing of
the following hypotheses:

1) There are differences in telomere lengths between trisomy 21 cells and their
isogenic euploid cells.

2) These differences in telomere length affect a subset of chromosomes, rather
than equally affecting all chromosomes.

3) There is an increased frequency of chromosomal instability in the trisomic
cells compared to euploid cells.
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Chapter 2

The use of array-based technology for mosaicism detection

Introduction

Mosaicism is a condition that denotes the presence of two or more cell lines that
originated from a single zygote, but differ in their genetic make-up as a result of
nondisjunction or mutation (Thompson and Thompson, 2004). Constitutional mosaicism
has been observed in both somatic and germ-line tissues in humans. In addition to
mosaicism, acquired somatic cell chromosomal changes can result in the presence of
multiple cell lines. The identification of mosaicism/cellular admixture is clinically
important, with its impact being especially relevant for evaluating cancer specimens, the
latter of which are becoming one of the largest needs in diagnostic testing.

Despite its rare incidence, constitutional mosaicism is a formidable diagnostic
challenge. Mosaicism has been reported for many different chromosomes and many
different types of abnormalities including monosomy, trisomy, triploidy, deletions,
duplications, translocations, rings and inversions (Schinzel, 2001). The clinical
significance of mosaicism has been documented in humans from the prenatal to postnatal
periods. During very early embryogenesis, chromosomal mosaicism has been shown to
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be an unexpectedly common event, being seen in 50% to 90% of very early embryos
studied through in vitro fertilization programs (Bielanska et al., 2002, Daphnis, et al.,
2005; Vanneste et al., 2009; Santos, et al., 2010). Furthermore, about 50% of all
spontaneous abortions have been conjectured to exhibit chromosomal mosaicism
(Vorsanova et al., 2005), but this latter value has not been consistently seen by other
investigators, with the variation in results possibly reflecting, at least in part,
methodological differences. Mosaicism has also been associated with postnatal
morbidity, including chromosomal syndromes, mental retardation and multiple congenital
malformations, autism and schizophrenia. Multiple cell lines arising from acquired
chromosomal changes have also been observed in a variety of health conditions,
including but not limited to Alzheimer disease and neoplasia (Youssoufian and Pyeritz,
2000; Yurov et al., 2008; Schinzel, 2001).

The tissue-specific distribution and percentage of cells having constitutional
mosaicism in an individual depends on the timing of the error, the cell lineage(s)
involved and the survival potential of the cells (Kalousek et al., 2000). The consequences
of mosaicism for an unbalanced cell line often are associated with greater clinical
consequences when the error occurs earlier in embryogenesis, since these cases tend to
have a higher percentage of abnormal cells and/or more tissues involved (especially if the
error arose prior to cell lineage differentiation). The results of a study reported by Hsu et
al., 1996 suggested that fetuses with a higher percentage of abnormal cells (>60 per cent)
were at a higher risk for abnormal outcomes, compared to fetuses with a lower
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percentage of abnormal cells (< 15 per cent). Often times, individuals with low-level
mosaicism may be overlooked because they have subtle phenotypes. However, some
patients with low-level mosaicism have been reported to have clinical outcomes (Yurov
et al., 2007; Shinawi et al., 2008). In addition, individuals with low-level mosaicism
could be at an increased risk for conceiving a child with a chromosomal imbalance since
the aberrant cell line may be present in their gametes (Smith et al., 1962; Hsu et al., 1971;
Mehes et al., 1973; Kaffe et al., 1974; Richards et al., 1974; Priest et al., 1977; Begleiter
et al., 1977; Werner et al., 1982; Meschede et al., 1998; Wise et al., 2009; Kovaleva and
Shaffer, 2003; Herrgård et al., 2007). Similarly, in conditions resulting from acquired
somatic cell aneuploidy, such as the hematological malignancies, the presence of a small
clone of cells having a chromosomal aneuploidy and/or rearrangement may be of great
clinical relevance for the management of the patient’s care, including decisions regarding
their diagnosis, prognosis prediction and selection of targeted therapeutic options
(Maciejewski et al., 2009).

Standard G-banding chromosomal tests may result in low-level mosaicism being
missed or misinterpreted as a culture artifact, since this analysis is typically limited to the
assessment of 20 metaphase spreads. G-banding analysis can also result in the failure to
identify mosaicism due to selective in vitro growth pressure that may favor cells having a
normal karyotype. When constitutional mosaicism is suspected, for example, due to a
patient having variegated skin pigmentation, hypomelanosis of Ito and/or growth
asymmetry (Donnai et al., 1988; Thomas et al., 1989; Woods et al., 1994), or when a
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small number of cells with significant chromosome abnormalities are detected in the
initial cytogenetic analysis, the examination of additional cells is usually indicated. In
general, when 20, 30, or 50 cells are evaluated without detection of mosaicism, the lowest
level of mosaicism excluded with at least 95% confidence is 14, 10 and 6%, respectively
(Hook, 1977). Theoretically, fluorescent in situ hybridization (FISH) is considered to be
an ideal laboratory technique for detecting mosaicism since cell lines that are present in
5% or fewer cells can be detected (Papavassiliou, et al., 2009; Dewald, et al., 1998).
However, scoring FISH is labor intensive, requires precedent knowledge of specific
chromosome abnormalities and also lacks whole genome coverage.

Recently, array-based technology has been developed and has shown several
advantages when compared with other existing techniques used for the analysis of
chromosomal abnormalities. It allows for genome-wide analysis at the highest resolution
of less than 700 bp; however, in practice, other parameters may influence the resolution,
such as experimental “noise” (which is often attributable to DNA fragmentation) and the
sensitivity of copy number measurements (Bernardini et al., 2010.). In addition to
improved resolution, another potential advantage of array-based diagnostic testing is that
cells can be evaluated without potential growth selection that might arise from an in vitro
culture system. In contrast, routine metaphase chromosome studies to detect
constitutional chromosomal changes require three (blood) to seven or more (prenatal
cases; products of conception) days of in vitro cell culture and aberrations that are smaller
than 3-10 Mb cannot be reliably detected (Shaffer and Bejjani, 2004). Although array-
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based technology has many strengths, it is limited in that it will not allow for the
detection of balanced chromosomal findings or polyploidy, which can be detected using
conventional G-banding methodologies.

Currently, two broad types of array-based technologies are used for clinical
cytogenetic testing; comparative genomic hybridization arrays (CGH arrays) and single
nucleotide polymorphism arrays (SNP arrays). In array CGH, patient DNA and control
DNA are labeled with different fluorochromes and then competitively hybridized to
arrays having DNA probes (e.g., bacterial artificial chromosomes array [BAC array] or
synthesized DNA fragments [oligonucleotide array] that are immobilized on glass, chips,
or beads). The fluorescent intensities of the case to control DNA values are then
compared to determine copy number alterations across the entire genome. The other type
of array, a SNP array, was originally designed for whole genome association studies, but
has been adapted for cytogenetic testing. Given that SNPs are not distributed evenly
across the genome, several of the original SNP-based microarray platforms were
modified for cytogenetics testing by incorporating additional copy number probes, the
latter of which allowed for increased genomic coverage of clinical relevant regions
(Maciejewski et al., 2009) and better detection of copy number changes. When compared
to array CGH platforms, SNP arrays have the additional advantage of allowing one to
simultaneously analyze copy number changes, as well as copy number neutral loss of
heterozygosity (LOH) and long contiguous stretches of homozygosity (LCSH), thereby
allowing for the recognition of uniparental disomy (UPD). For assessments using SNP
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arrays, patient DNA is labeled and hybridized to the microarray, with the results being
compared with a database of standard reference DNA values.

While several geneticists have confirmed the ability of array-based technology to
detect subtle or small abnormalities that were not perceived using conventional
cytogenetic testing, the ability of array-based technologies to detect the presence of
mosaicism remains controversial. A number of investigators have reported detecting a
mosaic complement in blood specimens from individuals that was missed by traditional
chromosomal analysis techniques (Table 3). Ballif, et al (2006) suggested that the array
presented an advantage for mosaicism detection since all nucleated blood cell lineages
could be evaluated (rather than just T-cells following mitogenic stimulation with
phytohemaglutin, as is the case for conventional cytogenetic testing). The results of case
reports, have led to a range of estimates regarding the lower detection limits of arraybased technology. Systematic studies that were completed with the goal of evaluating the
efficacy of array technology for mosaicism detection are few in number. The majority of
these systematic studies have been performed on “artificial mosaicism” samples that were
prepared by mixing blood or DNA samples from individuals having a known abnormal
chromosome complement with normal reference DNA (Ballif et al., 2006; Cheung et al.,
2007; Hoang et al., 2007). Investigators have often elected this approach due to the rarity
of constitutional mosaicism, which makes it difficult to ascertain multiple patients having
mosaicism for the same condition. While these laboratory created “mosaic” studies
provide insight as to the technical strengths of the array assay, they cannot fully mimic
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the experience that would be encountered when studying individuals having mosaicism,
the latter of whom might have variable proportions of the different chromosomal
complements in the total cell population (different cell types as noted above) that are
present in clinical specimens. Therefore, we carried out a blinded study designed to test
the efficacy of array-based technologies for detecting the trisomic cell lines present in
individuals having mosaicism for trisomy 21. The data obtained from this study allowed
for testing the following hypotheses: 1) The relative fluorescence intensities obtained
from microarray data, as measured by the smoothed mean of log2 ratios of all probes
across chromosome 21, are positively correlated with the percentage of trisomic cells
determined to be present in study samples using FISH methodology (the latter of which is
currently considered the “gold standard” for mosaicism assessment); and 2) Array-based
technology allows for the detection of mosaicism of a trisomic cell population that is
present in 15% or more cells.
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Materials and Methods

Study Participants
The study participants having mosaicism for trisomy 21 were recruited through
parental support groups [National Down Syndrome Congress (NDSC), the International
Mosaic Down Syndrome Association (IMDSA) website, newsletters and conferences]
and through clinical visitations. The only inclusion criterion was that the individual had a
confirmed diagnosis of mosaicism for trisomy 21 (usually based on GTG-banding studies
that were completed at or near the time of birth). After providing their informed assent
(children)/consent (parents or competent adults having mosaicism) (Virginia
Commonwealth University Institutional Review Board protocol #179), each study
participant provided a peripheral blood specimen, with some individuals also electing to
provide buccal smears for FISH studies. Confirmation and quantitation of the percentage
of trisomic cells present was done using FISH on cultured and/or uncultured
lymphocytes, as described below. Blood specimens were also evaluated from positive
controls (individuals having “complete” trisomy 21) and negative controls (individuals or
proficiency test specimens (College of American Pathology) having a previous diagnosis
that showed either a normal complement or a chromosomal finding that did not involve
chromosome 21). Specimens that were collected from control individuals followed the
same informed assent /consent procedures as those used for the study participants having
mosaicism (VCU IRB protocol #179). Prior to array specimen processing, the DNA
samples were coded to ensure that the investigators were blinded to the karyotype status
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of the specimens, thereby mimicking the scenario that would occur in the clinical
evaluation of patients using array technology.

Sample Collection and DNA Extraction
Three to five milliliters of peripheral blood was collected from each participant,
with DNA being extracted following standard procedures (Gentra Puregene, Qiagen,
Valencia, CA; manufacturer protocol). Prior to microarray analysis, all DNA samples
were quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE). Gel electrophoresis was also used for monitoring
potential DNA degradation. The quality control criteria used required that all DNA
samples processed for microarray studies have an OD-260/280 ratio between 1.80 and
2.00, with a major band size range of approximately10-20 kb.

SNP Array Hybridization and Analysis
The Affymetrix Genome-Wide Human SNP Array 6.0 was used for the SNP array
studies. This platform contains more than 906,600 SNP probes and more than 946,000
copy number (CN) probes. Each SNP probe contains 3-4 replicates per allele. The CN
probes include markers that are distributed evenly across the genome. The median
distance between probes for SNP and copy number assessments combined is less than
700 bp (Affymetrix Genome-Wide Human SNP Array 6.0 data sheet). Array experiments
were performed according to the manufacturer’s protocol (Affymetrix, Santa Clara, CA).
Briefly, a total of 500 ng of genomic DNA was digested with Nsp I and Sty I restriction
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enzymes. All fragments resulting from restriction enzyme digestion were ligated to Nsp I
and Sty I adaptors, which recognize the cohesive 4 base pair overhangs. The adaptorligated DNA fragments were subsequently amplified using a generic primer that
recognizes the adaptor sequence. PCR amplification products for each restriction enzyme
digest were combined and purified using magnetic beads (AMPure XP, Agencourt,
Beckman Coulter, Brea, CA), with the purified PCR products being fragmented with
DNaseI enzyme and end-labeled using a Terminal Deoxynucleotidyl Transferase (TdT)
enzymatic reaction. The labeled DNA was hybridized to an Affymetrix Genome-Wide
Human SNP Array 6.0 overnight. Following hybridization, the arrays were washed and
stained with streptavidin phycoerythrin (SAPE) and a biotinylated antibody using a
Fluidic Station 450. Following staining, the arrays were scanned using a GeneChip
Scanner 3000 7G.

The sample files generated from the scanner were processed using the Genotyping
Console Software Version 4.1.0 (Affymetrix, Santa Clara, CA) to assess data quality
control (QC) and generate copy number files (CNCHP file) for further analysis in the
Chromosome Analysis Suite Version 1.1 (ChAS) (Affymetrix, Santa Clara, CA).
Mosaicism was determined by inspection of: 1) the CN value (falling between 2 and 3 for
this cohort); 2) deviation of the log 2 ratio track from 0 and mean log2 ratio values
between 0 (2/2 copies) and 0.58 (3/2 copies); 3) alteration of allele difference patterns
(Figure 2); and 4) a smoothed log 2 ratio value that fell between 2 and 3 (Figure 2).
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CGH Array Analysis
CGH array experiments were performed using a CytoChip array according to the
manufacturer’s protocol (BlueGnome, Cambridge, UK). Each CytoChip array was
comprised of 4400 BAC clones with a median size of 565 kb and 1,357 subtelomeric
clones having a median size of 250 kb. Each clone had 4 replicates via a dye-swap
experimental design (for disease specific clones, each clone had 6 replicates). Random
priming was used to label test and reference control DNA samples, according to the
manufacturer protocol (BlueGnome). Briefly, a total of 800 ng of genomic DNA was
used, with 400 ng of DNA being labeled with Cy3 and Cy5 dyes, respectively. The same
quantity and labeling scheme was used for sex opposite reference DNA, the latter of
which was purchased as a pooled human DNA sample (Promega G1471-male and
G1521-female). After labeling, the test and reference DNA samples were run through an
AutoSeqTM G50 column and then checked for DNA yield and dye incorporation using a
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE).
After combining the test and reference DNA samples (i.e., Cy3-labeled test DNA and
Cy5-labeled reference DNA), the DNAs were ethanol precipitated and suppression
hybridized using human COT-1 DNA and herring sperm DNA in 10% dextran sulphate.
Following suppression hybridization, the DNAs were hybridized to the CytoChip array
and incubated at 37°C in a humidified hybridization chamber for 21-24 hours. Following
hybridization, non-specifically bound and unbound DNA was removed by washing in a
2X SSC/0.05% Tween-20 twice at room temperature for 10 minutes each, followed by
serial washing in 2X SSC/0.05% Tween-20 at 60°C for 5 minutes, 1XSSC at 60°C for 5
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minutes, 0.1X SSC at 60°C for 5 minutes, and 0.1X SSC at room temperature for 10
minutes. The array was immediately centrifuged to dry and scanned using a PerkinElmer
ScanArray Gx PLUS (PerkinElmer Life and Analytical Sciences, Shelton, CT) at 5 µm
resolution. The intensity data files were analyzed using the BlueFuse for Microarrays
software (BlueGnome, Cambridge, UK). Mosaicism was recognized by a deviation of the
log2 ratio values. The negative control specimens are expected to have a mean log2 ratio
for chromosome 21 equal to zero, while the expected copy number gain for positive
controls is 0.58 (a 3/2 ratio).

FISH Methodology
FISH was performed using probes specific for chromosome 21 (test probe) and
chromosome 13 (control probe) to determine the proportion of cells having trisomy for
chromosome 21. These studies were completed on cultured (72 hours) and uncultured
(blood smears) leukocyte nuclei as described previously (Papavassiliou, et al., 2009).
Briefly, for the cultured cell preparations, the slides were serial dehydrated 2 minutes
each in cold ethanol series (70%, 85%, and 100%). After air-drying, a 10μl aliquot of the
probe mixture (chromosome 21q22.13-21q22.2 - D21S259\D21S341\D21S1432;
chromosome 13q14 – RB1)(Abbott, IL) was added to the slides, with the target
chromatin and probes being co-denatured at 73°C for 2 minutes. Following hybridization
(at 37ºC for 4-16 hours), the non-specifically bound and excess probes were removed by
washing (0.4X SSC/0.3% NP-40 solution at 72°C for 2 minutes, followed by 2X
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SSC/0.1% NP-40 wash solution for 1 minute). The nuclear chromatin was then stained
using a DAPI/antifade solution (Abbott, IL).
For the uncultured preparations, an aliquot of blood was smeared on the slides (20
l of blood per slide) and air-dried. The slides were serially fixed in a modified Carnoy’s
fixative (3 parts of methanol and 1 part of acetic acid) at –20○C for 30 minutes. The
slides were then placed in 90% formamide in 2XSSC solution at 37○C for 5 minutes. The
slides were serial dehydrated for 2 minutes each in an ethanol series (70%, 85%, and
100%). After air-drying, a 10μl aliquot of the probe mixture (chromosome 21q22.1321q22.2 and chromosome 13q14) (Abbott, IL) was added to the slides. The target
chromatin and probes were co-denatured at 75°C for 10 minutes. Following overnight
hybridization, excess and unbound probes were removed by serial washing in 0.4XSSC at
72 °C for 2.5 minutes followed by 0.1% NP-40 in PBS at room temperature for 2
minutes. The nuclei were counterstained with DAPI/antifade solution (Abbott, IL).
Probe signals were visualized using a Zeiss Axiskop equipped with single
(Spectrum Orange, Spectrum Green) and triple band pass filters. In order to detect
mosaicism levels as low as 5% with greater than 99% power, a total of 1000 cultured
blood lymphocyte nuclei, and 500 uncultured blood nuclei were scored for each study
participant (Dewald et al., 1998).
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Results

SNP arrays were processed for 31 DNA samples, including 13 samples from
individuals with mosaicism for trisomy 21, 13 samples from individuals having a
previous diagnosis that showed either a normal complement or a chromosomal finding
that did not involve chromosome 21 (negative controls) and 5 samples with a previous
diagnosis of full or partial (due to a structural change that was in every cell) trisomy 21
by G-banding analysis (positive controls). BAC arrays were processed on 10 DNA
samples, including 6 samples from individuals with mosaicism for trisomy 21, 3 samples
from individuals with chromosome abnormalities that did not involve chromosome 21
(negative controls) and 1 individual with a previous diagnosis of full trisomy 21 (positive
control). In a Table 5 a summary of the microarray results obtained from both array
platforms is presented. The results of each case are compared to previous cytogenetic
analyses and indicate the percent mosaicism observed by the FISH compared to
microarray methodologies.

As expected, the CN for chromosome 21 detected in each of the negative control
cases was equivalent to 2 (no aberrations noted). In addition, abnormalities involving
other chromosomes that were present in these cases were correctly identified with no
additional clinically relevant aberrations being detected. The background level of cells
having gains involving chromosome 21 based on the SNP microarray analysis in the
negative control group ranged from 0% to 4%. Using only the CN state values calculated
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by the ChAS software (which has criteria requiring 30% or higher mosaicism for
detection), only 5 of the 13 mosaic cases were detected, with their estimated percentage
of trisomic cells ranging from 28% to 100%. By expanding the ChAS software analysis
to include an assessment of the smoothed signal, a total of 8 of the 13 individuals with
mosaicism were readily identified as having mosaicism, with a case having 15% trisomic
cells being detected. A mosaic case having 10% trisomic cells showed subtle changes
from the non-mosaic cases, but yielded a value that was equivocal and thus not clearly
defined as mosaicism (Figure 2). In two individuals having approximately 19% trisomic
cells as determined by FISH, the SNP array patterns were within normal limits (false
negative). Interestingly, two individuals with mosaicism involving approximately 80%
trisomic cells, as determined by FISH, had an array value that was consistent with nonmosaic (“full”) trisomy 21.
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Table 5: Summary of microarray results in 30 study subjects
%FISH
Karyotype
CPB

UPB

Log2
ratio

Affymetrix Genome-Wide Human SNP 6.0
Smooth signal
Gain for ch.21 detected
of ch.21
%Array
Allele
Smooth CN
Mean
SD
calling
difference
signal

Mean
log2
ratio of
ch.21

BlueGnome CytoChip
log2 ratio of
ch.21
Gain for
ch.21
detected
Mean
SD

Negative Controls (2 copies ch.21 in all cells)
46,XY,del(3)(q29)

N

N

N

N

3

2.025

0.124

0.008

N

0.003

0.058

46,XX,dup(3)(q26.1),del(8)(p23.2)

N

N

N

N

0

1.980

0.127

-0.010

N

0.015

0.048

46,XY,dup(16)(q22.2q23.2)

N

N

N

N

4

2.036

0.233

0.009

N

0.009

0.057

46,XY,dup(10)(p13p15.3)

N

N

N

N

0

1.995

0.386

-0.003

46,XY,del(18)(p11.2)

N

N

N

N

2

2.016

0.089

0.006

46,XY,del(8)(p23.1p23.3),dup(8)(p21.1p22)

N

N

N

N

0

1.907

0.123

-0.040

46,XX

N

N

N

N

0

1.895

0.155

-0.045

46,XY

N

N

N

N

0

1.941

0.153

-0.026

46,XX,del(17)(p11.2p12 )

N

N

N

N

3

2.030

0.139

0.010

N

-0.024

0.075

46,XX

N

N

N

N

3

2.028

0.153

0.009

N

-0.030

0.059

46,XY,del(2)(q14.1q14.3),dup(22)(q11.21q11.21)

N

N

N

N

2

2.023

0.121

0.008

46,XY,dup(5)(q33.3q35.3),del(13)(q34)

N

N

N

N

1

2.014

0.123

0.004

46,XY,dup(17)(p11.2p12),del(17)(q11.2q12)

N

N

N

N

3

2.033

0.112

0.012

N

0.012

0.041

0.381

0.064

Mosaic Tri 21
mos 47,XX,+21/46,XX

93.6

80.4

Y

Y

Y

Y

100

3.088

0.178

0.347

Y

mos 47,XY,+21/46,XY

50.5

63.2

Y

Y

Y

Y

50

2.498

0.147

0.177

Y

0.216

0.083

mos 47,XY,+21/46,XY

48

26

Y

Y

Y

N

21

2.212

0.155

0.079

N

-0.049

0.102

mos 47,XX,+21/46,XX

90.5

78.5

Y

Y

Y

Y

100

3.160

0.183

0.365

mos 47,XX,+21/46,XX

24.9

28

N

N

S

N

7

2.068

0.150

0.025

mos 47,XX,+21/46,XX

21

19.4

N

N

N

N

0

1.970

0.140

-0.014

mos 47,XX,+21/46,XX

18.7

19

N

N

N

N

0

1.960

0.151

-0.018

mos 47,XY,+21/46,XY

29.5

Y

Y

Y

N

20

2.199

0.146

0.074
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Table 5: Summary of microarray results in 31 study subjects (continued)
Affymetrix Genome-Wide Human SNP 6.0
Smooth signal
Gain for ch.21 detected
of ch.21

%FISH

Mean

SD

Mean
log2
ratio of
ch.21

66

2.659

0.157

0.227

15

2.147

0.141

0.055

N

8

2.079

0.131

0.030

Y

28

2.279

0.223

0.101

S

N

10

2.099

0.150

0.037

Y

Y

Y

100

3.181

0.272

0.369

Y

Y

Y

Y

51

2.511

0.282

0.177

Y

Y

Y

Y

100

3.162

0.236

0.365

Y

Y

Y

Y

100

3.072

0.236

0.342

Y

Y

Y

Y

100

3.051

0.188

0.242

Karyotype
CPB

UPB

Log2
ratio

Allele
difference

Smooth
signal

CN
calling

mos 47,XY,+21/46,XY

62

53

Y

Y

Y

Y

mos 47,XX,+21/46,XX

23.2

20

S

N

Y

N

mos 47,XY,+21/46,XY

6.5

17

N

N

S

mos 47,XX,+21/46,XX

43

41

Y

Y

Y

mos 47,XY,+21/46,XY

10.4

8.5

N

N

47,XX,+21

96.8

89.4

Y

47,XY,der(21)(q10;q10)

81.5

47,XY,+21

97.6

47,XX,+21

97.2

% Array

BlueGnome CytoChip
log2 ratio of
ch.21
Gain for
ch.21
detected

Mean

SD

Y

0.357

0.047

Mosaic Tri 21

Positive control (3 copies of ch.21 in all cells)

46,XX,der(21)(qter→q21::p11.1→qter)

ch.21 = chromosome 21, Tri 21 = trisomy 21, CPB = cultured peripheral blood, UPB = uncultured peripheral blood, CN = copy number, SD =
standard deviation, Y = yes, N = no, S = suspicious
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In practice, the manufacturer recommended protocol for detecting mosaicism in a
specimen is to combine the data collected from all analyses, including the log2 ratios,
smoothed signals and especially the allelic patterns. By expanding the assessments to
include each of thesfore data points, the current version of the ChAS software
consistently allowed for the detection of a minor cell population that was present in
approximately 20% of cells (20% to 80% trisomic complement)(Figure 2).
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(a)
0.6

(b)
1.5
0.5
-0.5
-1.5

(c)

Figure 2: Composite array results of representative cases having mosaicism for trisomy21. Each box in this figure
represents a different individual, with a total of 8 patients being shown. The percentage values below the data indicate the level
of trisomic cells present in each person, with 0% representing an individual having a normal (2 copies) complement for
chromosome 21 and 100% representing an individual with “complete” trisomy 21. The results of the ChAS findings from
different analyses are shown, including the log2 ratio (a); the allelic patterns (b) and the smoothed signal (c). The mean log 2
ratios (a) are shown as a light blue line in the middle of the marker data values and range from 0 (0% trisomy) to 0.6 (100%
trisomy). (b). The allele difference track shows allele patterns observed in euploid ( where A allele = 0.5 and B allele = -0.5
and AA = 1; AB = 0; and BB = -1) compared to trisomic (AAA = 1.5, AAB = 0.5, ABB = -0.5 and BBB = -1.5) cells. (c) The
smooth signal of log2 ratio track shows an increase of the signal from 2 to 3, corresponding with 2 to 3 copies of chromosome
21.
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For the positive control cases, the SNP array evaluation of 4 of the 5 specimens
was consistent with the GTG banding karyotypic results. However, one case, who was
referred for assessment due to a phenotype suggestive of mosaicism (presence of
hypomelanosis of Ito), had an array result that was discrepant to the findings of the
conventional cytogenetic analysis. The chromosome analysis showed the presence of
secondary trisomy for chromosome 21 [der(21)(q10;q10); either an isochromosome or a
Robertsonian translocation] in each of the 30 metaphase spreads examined (100%).
Interestingly, the array result was consistent with the presence of trisomy mosaicism for
both chromosome 14 (62% of cells) and chromosome 21 (51% of cells). To
confirm/refute these array findings, additional analyses were completed using FISH with
two probe sets. Probe set one included a probe that was specific for the long arm of
chromosome 14 (specific for 14q.32; spans the IGH region), with a control probe also
being evaluated (specific for band 11q13; spans the CCND1 breakpoint region). Probe set
two included a probe that is specific for band 21q22 (D21S259\D21S341\D21S1432),
along with a control probe from chromosome 13 (spans the 13q14; RB1locus) (Figure 3).
An assessment of 500 interphase nuclei per probe set confirmed the presence of
mosaicism for both chromosomes, with three signals being present for the chromosome
14 probe in 22% of intephase nuclei and three signals for the chromosome 21 probe in
81.5% of interphase nuclei.
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(a) Chromosome 14

(b) Chromosome 21

1

1

2

2

3

3

4

4

(c)

(d)

(e)

Figure 3: Detection of mosaicism for trisomy 14 and a trisomic dose of 21q. Mosaicism was determined from CN state (1),
log2 ratio (2), allele difference (3) and smooth signal (4) tracks for chromosome 14 (a) and chromosome 21 (b). Interphase
analysis on cultured lymphocytes (c), using a locus specific probe mixture for chromosome 14 (green) and for chromosome 11
(red) showed cells having 3 (lower left) or 2 (upper right) signals for the chromosome 14 probe. Interphase analysis on
cultured lymphocytes (d), using a locus specific probe mixture for chromosome 21 (red) and for chromosome 13 (green)
showed cells with 3 (lower right) and 2 (upper left) signals for chromosome 21. (e) Metaphase spread showing a trisomic dose
of the long arm of chromosome 21 due to a der(21)(q10;q10).
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A SNP array was also processed using a DNA sample from an individual with
partial trisomy for chromosome 21, which resulted in her having a trisomic dose of
21q21 to 21qter (Figure 4). The array result was consistent with the findings of the GTGbanding and allowed for refinement of the breakpoint in the rearrangement to band
21q21.2 (Figure 4).

A potential advantage for using a SNP array was illustrated by a case having
mosacism with 20% of cells that were trisomic based on the array analysis (Figure 5). In
this specimen an allelic pattern consistent with the presence of 3 distinct chromosomes 21
was seen for the proximal long arm markers, with the distal long arm markers showing a
shift in the allele pattern that could indicate the location of a meiotic recombinational
event (Figure 5).

The collective information gained from the assessments of the mosaic probands
and the positive and negative control subjects, was used to determine if the proportion of
trisomic cells estimated from the SNP array, as measured by the smoothed mean of log2
ratios of all probes across chromosome 21, correlated with the percentage of trisomic
cells determined by the “gold standard” FISH methodology (Figure 6). These values were
positively correlated, with no significant difference being detected in the percentage of
trisomic cells quantified using the SNP array compared to the FISH analysis that was
completed on uncultured lymphocytes (p-value = 0.80, paired t-test), or on the cultured
lymphocytes (p-value = 0.30, paired t-test).
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CN state

Log2 Ratio

Allele Difference
46,XX,der(21)(qter→q21::p11.1→qter)
Smooth Signal

Figure 4: SNP array result of an individual with partial trisomy for chromosome 21 due to a structural abnormality.
Note the increased log2 ratio, and smooth signal, and altered allele difference pattern at 21q21.2 (position 24,959,394) (arrow)
with 3 doses continuing for the rest of the long arm. The SNP array result is in agreement with the findings of the GTGbanding analysis which showed a partial trisomy, with a breakpoint at 21q21 (as evidenced by the reduced thickness of the
21q21 dark band in the upper portion of the derivative chromosome 21 when compared to the bottom portion of the derivative
chromosome).
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CN state
Log2 Ratio

Allele Difference

Smooth Signal

Figure 5: SNP array result of chromosome 21 showing an altered allelic pattern. Probable meiotic recombination events
involving loci at 21q21.3 (position 29,989,702-31,288,209) (small arrows), and 21q22.12 (position 37,050,935-47,983,657)
(large arrows) occurred during meiosis I, leading to alterations in the allelic patterns in this individual with 20% of trisomy
21cells.
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100

Percentage of trisomy 21 cells

80

60

40

20

0
1.5

2.0

2.5

3.0

3.5

Mean of smoothed log2 ratios of all probes across chromosome 21

Figure 6: Mean of smoothed log2 ratios of all probes across chromosome 21 and
percentage of trisomy 21 cells as determined by FISH. The data are shown with the
mean and SD of the smoothed log2 ratios for the negative controls (blue), individuals
with mosaicism for trisomy 21 (red) and positive trisomic controls (green). The blue box
shows zone of normal copy number (CN of 2), the pink box shows the mosaicism zone
and the green box shows the zone of complete trisomy 21 (CN of 3). Note the positive
correlation between mean of the smoothed log2 ratios and percentage of trisomic cells
(Pearson correlation, r = 0.88, p-value <0.00001).
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The BAC array CGH platform was used to process a total of 10 DNA samples,
including 6 negative control samples, 3 samples from individuals with mosaicism for
trisomy 21 and 1 sample from an individual with full trisomy 21 (Table 5 and Figure 7).
The BAC array provided findings that were consistent with those of conventional Gbanding results for each of the negative control cases, with no gain of chromosome 21
being detected in any of these samples. A gain of chromosome 21 was detected in the full
trisomy 21sample and in 2 of the 3 mosaic cases. The mosaic case that was not readily
identified had 26% trisomic cells in the FISH assay and did show a subtle deviation of the
log2 ratio, but this variance was too equivocal to allow for clear categorization as a
mosaic case (Figure 7b). This same patient was correctly categorized as a mosaic using
the SNP array.

A comparison of the potential correlation between trisomic values detected using
the BAC array compared to FISH analyses and the SNP array was completed (Figure 8).
The estimates of trisomic cells present in individuals (based on the mean log2 ratio of all
probes across chromosome 21) from both array platforms were positively correlated with
the values obtained in the FISH assay. Furthermore, for 2 of the 3 mosaic cases evaluated
with both platforms, there was good agreement for the estimated proportion of trisomic
cells present.
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(a)

(b)

(d)

(e)

(c)

Figure 7: Array CGH results for chromosome 21 using a BAC array platform. This figure shows the results from 5
subjects including: (a) an individual with a normal chromosome 21 complement (log 2 ratio of 0 as expected with 2 copies);
(b) an individual with 26% trisomic cells determined by FISH on uncultured lymphocytes, which shows subtle deviations from
the log2 ratio (suggestive of mosaicism but not definitive); (c) an individual with 50% trisomic cells as determined using FISH
on uncultured lymphocytes, which shows gains (log 2 ratio of 0.3 or more) for several of the BACs evaluated from
chromosome 21 (green line); (d) an individual with 80% trisomic cells on uncultured lymphocytes, showing a value consistent
with “full” trisomy 21; and (e) an individual with “full” trisomy 21 that has a log 2 ratio consistent with trisomy 21 (but less
than the theoretical value of 0.58 as expected for 3/2 copies).
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100.0
90.0
Trisomy 21 percentage

80.0
70.0
60.0
50.0
40.0

- - - - y = 238.14x + 7.0341
R² = 0.9014

30.0
20.0

____ y = 212.16x + 6.99
R² = 0.8867

10.0
0.0
-0.10

0.00

0.10

0.20

0.30

0.40

0.50

Mean log2 ratio of probes across chromosome 21

Figure 8: Comparison of the proportion of trisomic cells detected using SNP array,
BAC array and FISH methodologies. The mean log2 ratios for chromosome 21 from
SNP (○) or BAC (∆) arrays are presented on the X axis, with the percentage of trisomic
cells as determined using FISH, being presented on the Y axis. The data points shown for
each individual are the mean values for the negative controls (blue), individuals with
mosaicism for trisomy 21 (red) and positive controls (green). Note the nearly parallel
trend lines of the SNP (dashed line) and BAC (solid line) platforms.
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Discussion

These studies have shown that array-based technology has both strengths and
weaknesses in its ability to detect the presence of chromosomal mosaicism. Using the
default software analysis setting for CN state, we were unable to detect trisomic cell
populations that were present in less than 30%, due to the software categorization of log2
ratio changes from 0-30% as copy number neutral findings. Thus, it is important to
include analyses of mosaic cases in laboratory validation studies to ensure that the
software criteria are defined in a manner that is congruent with the level of detection for
mosaicism that is desired by the lab. In addition to log2 ratio values, SNP arrays provide
information about the allelic patterns present in each case. While these patterns were very
useful for confirming suspected cases of mosaicism, in our experience the use of allele
pattern assessments did not allow for the recognition of additional cases that were
undetected using the log2 ratios, or the smoothed signal values.

For the SNP microarray platform (Affymetrix 6.0) and analysis software (ChAS)
used, the smooth signal assessment tool provided the most efficient means for detecting
mosaicism. Based on the collective information gained from all assessment tools for the
13 cases evaluated, no significant difference was detected in the quantitative percentage
of trisomic cells estimated using microarray compared to FISH technologies. However,
categorically, the microarray studies resulted in 2 false negative diagnoses (with both
cases having less than 20% trisomic cells) and 2 cases that would have been misclassified
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as “full” trisomy that were truly mosaic (80% or more trisomic cells). Furthermore, for 3
cases (2 of which had approximately 10% trisomic cell populations), detection of the
trisomic cell line was subtle/equivocal and limited to an assessment of the smooth signal
value and would have been missed using the other analysis assessments. Nonetheless,
these specimens were distinguished as candidates for additional reflex testing with FISH
to confirm/refute the possible presence of low level mosaicism. However, without
experience in scoring mosaic cases, these subtle results may well have been misclassified
as normal, which would have reduced the sensitivity to 0.62. Therefore, as noted above, it
is important that geneticists who are interpreting the results of microarray findings gain
experience in the assessment of cases having mosaicism to improve the likelihood that
they will recognize cases.

There are several explanations for the incongruity between microarray and FISH
and/or G-banding studies. Firstly, the DNA used for the microarray studies is collected
from all types of leukocytes, while the G-banding studies are performed on T
lymphocytes, (following ohytohemaglutinin [PHA] stimulation). Secondly, it is possible
that in vitro selective growth differentials contribute to the discrepancy. Thirdly, the cells
evaluated in the microarray studies represent a composite of the total cell population
(average) value, whereas the FISH analyses allow for the recognition of single cell
aberrations, making FISH the more sensitive technology for detection of mosaicism if a
known target can be anticipated.
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Using the current software analysis tool sets supplied by the array vendors, this
study showed that levels of mosaicism that were greater than 15% to 20% were
consistently detected (Figure 2). This result is in close agreement with the findings of
previous investigators who denoted the ability to detect cell mixtures synthesized to have
10% to 20% “mosaicism” using array CGH platforms (Ballif et al., 2006; Cheung et al.,
2007; Hoang et al., 2007). In one investigation, a SNP array was reported to be have the
ability to detect mosaic cell lines that were present in as few as 5% of the total cell
population (Conlin, et al., 2010). These investigators suggested that a key advantage of
using a SNP array for mosaicism detection is that one has allelic patterns, as well as copy
number changes, to aid in the interpretation of cell lines having mosaicism (Conlin, et al.,
2010).

In this study, we demonstrated that both the BAC and SNP platforms could detect
mosaicism, with their results being consistent for two of the three cases evaluated using
both platforms. This inability to identify the one case having mosaicism using a BAC
array could be explained by the smaller number of probes analyzed for chromosome 21
(52 BAC clones versus 24,170 SNP and CN probes). However, this study was not
designed to compare the performance between SNP and BAC arrays, since the number of
study subjects (31 cases versus 10 cases) varied between platforms, being limited to only
3 cases having mosaicism for the BAC array (due to cost limitations).
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While limitations of arrays for identifying mosaicism were observed in this study,
it also showed the strength of array-based technology to identify previously unrecognized
chromosomal mosaicism. Specifically, the array studies allowed for the detection of
mosaicism for trisomy 14 that was not identified in a conventional GTG-banding study.
However, an assessment of the percentage of trisomic cells present in this specimen
varied between the FISH and SNP array assays, with the percentage in arrays being
higher for trisomy 14 (62% compared to 22%) and lower for trisomy 21 (51% arrays;
81.5% FISH; 100% GTG-banding). Possible explanations for the observed variations in
frequencies of cell lines include: (1) selective growth pressure against the trisomy 14
cells in the in vitro culture system used for the FISH and GTG-banding studies; (2) a
higher proportion of trisomy 14 complements in the total leukocyte cell population when
compared to the T-cell population, the latter of which is preferentially present in the in
vitro cultures due to stimulation using PHA; or (3) a potential influence of having used an
archival heparinized blood specimen for the DNA extraction.

One major advantage for using a SNP array is that, when combined with parental
studies, one can infer the origin of the segregation error (i.e., meiosis I versus meiosis II
and mitosis) that resulted in the presence of the extra chromosome in the trisomic
individuals. However, these patterns were difficult to distinguish when the percentage of
trisomic cells was low. When the proportion of trisomic cells was 50% or more, one
could confidently differentiate between meiosis I and meiosis II/mitosis errors. Also, an
analysis of alleleic patterns can allow for the recognition of recombination events, which
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can be helpful for confirming the presence of mosaicism in specimens having less than
50% trisomic cells, as seen in Figure 5.

In summary, our study demonstrates that array-based technology is effective for
detecting mosaicism that is present in 20% or more cells. However, FISH remains the
“gold standard” for mosaicism detection and should be considered for confirmation when
low level mosaicism is suspected and/or to confirm/refute equivocal array-based results.
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Chapter 3

Chromosome-specific telomere length profiles in euploid and trisomic cells obtained
from individuals having mosaicism for Down syndrome

Introduction

The growing number of elderly individuals in our population has caused an
increased concern about the management of future healthcare needs and costs. It has been
estimated that the number of people aged 65 years or older will increase from
approximately 35 million in 2000 to 71 million in 2030, with the number of people who
are age 80 years or older being expected to increase from 9.3 million in 2000 to 19.5
million in 2030 (www.cdc.gov/mmwr/).This increase in our need for services related to
aging individuals underscores the necessity to have a better understanding of the
mechanisms of aging and age-related health conditions, with the ultimate goal of
improving our ability to diagnosis, treat and possibly prevent age-related diseases such as
cancers, and neurodegenerative diseases (i.e., Alzheimer disease). To better understand
the mechanisms underlying aging and age-related diseases, different study models have
been utilized. For example, investigators have studied biological measures collected from
centenarians or other older individuals compared to those observed in young individuals.
However, interpretation of the results of these studies can be confounded by differences
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in genetic backgrounds, environmental exposures and co-existing health conditions. One
approach that can be used to test the contribution of genes on the aging phenotype is to
study individuals who have mutations that cause them to have premature aging, such as
Hutchinson–Gilford Progeria syndrome and Werner syndrome (Crabbe, et al., 2007;
Ariyoshi, et al., 2007; Cao, et al. 2011). Individuals with Down syndrome have also been
observed to age prematurely. In particular, people with Down syndrome have an
increased risk for developing an early onset of Alzheimer disease (Potter, 1991; Roth et
al., 1996).

The results of the many studies focused on understanding aging have shown that
both genetic and environmental factors play an important role in the etiology of normal
aging and the acquisition of age-related conditions in humans. One genetic factor that has
been implicated in the aging process and development of age-related diseases is the
shortening of telomeres. A telomere is a specialized structure at the end of a chromosome
that consists of tandem repeats (TTAGGG/CCCTAA)n and telomere associated proteins,
including TRF1, TRF2, TIN2, TPP1, Rap1 and POT1 (Aubert and Lansdorp, 2008).
Telomeres play an important role in maintaining structural integrity of chromosomes by
keeping the chromosome ends intact and preventing the single stranded tip that results
from incomplete replication from being recognized as DNA damage (Blackburn, 2005).

The protective function of the telomere was first recognized by Muller (1938) and
McClintock (1941). McClintock noted that without a telomere, a chromosome’s ends
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would fuse and causes genomic instability. In 1961, Hayflick and Moorhead
demonstrated that cultured cells have a limited number of divisions they complete before
entering a senescence phase. This phenomenon is known as the “Hayflick limit”. In 1973,
Olovnikov was the first to recognize the “end replication problem”. He proposed that
following each round of replication, cells lose small segments of DNA due to DNA
polymerase being unable to fully replicate the chromosome ends. This phenomenon is
ultimately thought to lead to cell death when telomeres reach critically short lengths. At
the cellular level, the mechanism whereby telomere shortening triggers replicative
senescence and cell death is unclear. It has been speculated that telomere shortening may
trigger a TP53 DNA damage response (Davis et al., 2003).

Telomere attrition has been conjectured to play a causal role in aging (Mayer et
al., 2006) and has also been associated with a number of health conditions, including, but
not limited to, neoplasms (de Lange, 1994; Shay, et al., 1993;Autexier and Greider, 1996;
Blackburn, 2005; Gerashchenko, 2010; Ma, et al., 2011, Donate and Blasco, 2011);
atherosclerosis (Benetos et al., 2004); heart failure (Wong et al., 2008); obesity (Valdes,
et al., 2005); rheumatoid arthritis (Schonland et al., 2003); stress (Epel et al., 2004);
chronic schizophrenia (Yu et al. 2008); dyskeratosis congenita (Vulliamy et al., 2004);
Alzheimer disease (Panossian et al. 2003); premature aging syndromes (such as
Hutchinson–Gilford Progeria syndrome and Werner syndrome [Crabbe et al., 2007;
Ariyoshi et al., 2007; Cao, et al., 2011]); chromosome instability syndromes (such as
ataxia telangiectasia, Bloom syndrome and Fanconi anemia [reviewed in Callén and
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Surrallés, 2004]); and Down syndrome (Vaziri et al., 2003; Jenkins et al., 2006; Jenkins
et al., 2008). Telomere length has also been speculated to influence mortality (Cawthon,
et al., 2003).

In most somatic cells, the telomere shortens with each cell division due to the end
replication problem. This shortening is thought to occur in cells that lack telomerase.
Telomerase, which was discovered by Blackburn and colleagues (Greider and
Blackburn,1985; Shampay and Blackburn 1988; Greider and Blackburn, 1989), is a
specialized enzyme that maintains telomere length by adding TTAGGG repeat sequence
to the 3' end of DNA strands in the telomere regions, thus maintaining telomere length
(reviewed in Chan and Blackburn, 2004; Aubert and Lansdorp 2008). Telomerase
activity is present in germ cells, but not in most somatic cells, leading to somatic cells
having a limited lifespan. However, in some cell types, telomere length can be
maintained by an alternative pathway (ALT) involving homologous recombination
between telomeric or subtelomeric sequences (reviewed in Mefford and Trask, 2002).

Besides the end replication problem, investigators have shown that oxidative
damage of the telomeric sequence could be a major cause of telomere shortening. This
finding was supported by antioxidant treatment with a free radical scavenger, which was
able to reduce telomere shortening in cultured fibroblasts (Von Zglinicki, 2000). One of
the key enzymes involved in free-radical metabolism is superoxide dismutase (SOD-1),
which is encoded by the SOD-1 gene on chromosome 21. In individuals with Down
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syndrome, SOD-1 activity is increased due to triplication of chromosome 21, with this
increase being disproportionate to the activity of the downstream enzymes responsible for
removal of hydrogen peroxide (e.g., glutathione peroxidase). It has been speculated that
this imbalance may contribute to premature telomere damage in trisomy 21 cells by an
accumulation of hydrogen peroxide.

To date, only a few investigators have studied the relationship between telomere
length and Down syndrome. Using a terminal restriction fragment (TRF) telomere assay,
which provides an overall average telomere length, Vaziri et al. (1993) observed a
significantly higher rate of telomere loss (133 ± 15 bp/year) in people having Down
syndrome compared with age-matched controls (41 ± 7.7 bp/year). In addition,
individuals with Down syndrome who have dementia/Alzheimer disease or mild
cognitive impairment have been reported to have shorter telomeres than individuals with
Down syndrome without these conditions (Jenkins et al, 2006; Jenkins et al., 2008). One
limitation in interpreting the results from these previous studies is that the observed
differences in telomere length (which is a heteromorphic trait) reflect variations between
unrelated individuals who, in addition to having Down syndrome, also have differences
in their genetic make-up and environmental exposure histories.

Twin studies, comparing identical to non-identical twins or identical twins who
are discordant for a phenotype/exposure, are one of the most powerful model systems for
teasing apart the contribution of genetic versus environmental influences on a trait.
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Another interesting experimental approach for recognizing genetic differences
attributable to genetic imbalance is to study individuals having mosaicism, because an
individual with mosaicism has 2 or more genetically distinct cell lines that develop within
a single zygote and differ only by chromosomal nondisjunction. Despite it is rarity,
mosaicism for trisomy 21 is a fascinating condition to study for gaining insight about
aging and Alzheimer disease since individuals with mosaicism have two types of cells
(i.e., euploid and trisomy 21) that are identical for environmental exposure and nearly
identical for their genetic background (i.e., only different by the number of chromosomes
21).

Therefore, this study was performed to evaluate the impact of having a trisomic
dose of chromosome 21 on telomere length. By comparing trisomic to euploid cells from
individuals having mosaicism for Down syndrome, one could minimize inter-individual
differences arising from other genetic/environmental influences. In addition, by utilizing
FISH methodology with a telomere-specific probe on metaphase chromosomes,
combined with comparative genomic hybridization (CGH) technology, one can compare
“chromosome-specific” telomere lengths from euploid cells to trisomic cells obtained
from individuals having mosaicism for trisomy 21. Lastly, while there have been
previous reports of telomere lengths in older individuals having Down syndrome, there
have been no reports of the telomere lengths in children. The data derived from this study
allowed for a direct testing of the following hypotheses: (1) Differences in telomere
length can be detected between cell types based on their genetic make-up; (2) Telomeres
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are shorter in cells having a trisomic dose of chromosome 21 compared to cells having a
euploid (2 copies) dose; (3) Telomere attrition can be observed as a biological change
that occurs during early childhood in a cell having a trisomy 21 complement; (4)
Telomere attrition associated with trisomy 21 affects all chromosome equally, rather than
having a targeted effect on a subset of chromosomes.
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Materials and Methods

Study Participants
Participants were recruited through the National Down Syndrome Congress
(NDSC) meeting (Washington D.C., 1995), announcements made in national and local
Down syndrome support groups, newsletters, the International Mosaic Down Syndrome
Association (IMDSA) (via their website and IMDSA conferences) and through visits for
genetic counseling. The only inclusion criterion for study participation was that the
individual had a confirmed diagnosis of mosaicism for trisomy 21. All families have
given informed consent to participate in this study, which has been approved by the
Virginia Commonwealth University Institutional Review Board (protocol #179).

Cell Cultures
Duplicate stimulated lymphocyte cultures were established and harvested
according to standard protocols [RPMI 1640 media, supplemented with 15% fetal bovine
serum (FBS) and phytohemaglutinin (PHA)]. A total of 72 hours after culture initiation,
the lymphocyte cultures were harvested as described previously, with colcemid being
added 15 minutes prior to harvest to enrich the specimens for cells that were in the
mitosis portion of the cell cycle (Leach and Jackson-Cook, 2001).

The lymphocyte chromosome preparations that were used in this study were
obtained from archival cell pellets that were harvested from 2004 to 2009. These archival
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pellets were kept in a modified Carnoy’s fixative (3 parts of methanol and 1 part of acetic
acid) at -20oC. To reduce cytoplasm, which might compromise probe hybridization, the
cell pellets were washed in Carnoy’s fixative twice before the cell solutions were dropped
onto the slides using a Thermatron (temperature of 22±1C and humidity of 48±2%). The
slides were reviewed with a phase contrast/bright field microscope to ensure that the
quality of the preparation was adequate for the FISH study (number of
metaphases/interphase nuclei and quality of preparation [lack of cytoplasm]). After
review, the slides were placed on a hot plate at 60C for an hour, followed by aging at
room temperature for 1-2 weeks. Alternatively, rather than aging at room temperature, for
a portion of the cells the aging was induced by soaking the slides in 2xSSC for 10
minutes prior to the FISH experiment. If cytoplasm was present, the slides were soaked in
Carnoy’s fixative for 1 additional hour before proceeding with probe hybridization.

Chromosome-Specific Telomere Length Assay
Metaphase chromosomes were hybridized with a telomere-specific FITC-labeled
synthetic peptide nucleic acid (PNA) probe following the manufacturer’s protocol
(DakoCytomation, Denmark). In addition, an FITC-labeled probe that is specific for the
pericentromeric region of chromosome 2 was simultaneously hybridized to the metaphase
spreads as a control (and to serve for standardization of intensity values from cell to cell)
(Mayer et al., 2006). Briefly, slides were fixed in cold Carnoy’s fixative for 1 hour. After
air-drying, the slides were rinsed with 1xTBS (Tris-Buffered Saline, pH 7.5) for 2
minutes, fixed in 3.7% formaldehyde in 1xTBS for 2 minutes and then rinsed (twice in
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1xTBS for 5 minutes). The slides were then immersed in a pre-treatment solution
containing proteinase K, for 10 minutes, rinsed (twice in 1xTBS for 5 minutes) and
dehydrated (using a cold ethanol series [70%, 85% and 100%]). After air-drying, a
cocktail probe mixture (11µl of FITC-labeled telomere specific probe and 1 µl of FITClabeled centromere-2 probe per subject [a half slide area]) was added to each slide and
the probe and metaphase spreads co-denatured in a thermocycler at 80oC for 3 minutes.
After hybridization in a dry hybridization chamber at room temperature for 2 hours, the
excess and unbound probe was removed by rinsing (once in a manufacturer provided
rinse solution at room temperature for 1 minute, followed by 5 minutes in a manufacturer
provided wash solution at 65oC). Following serial dehydration in a cold ethanol series
(70%, 85% and 100%), the slides were air-dried and counterstained with a 5:1
DAPI/propidium iodide solution.

The telomere lengths of each chromosome were assessed using a semiquantitative FISH method (CGH software from Applied Imaging Cytovision System) as
described by Leach et al. (2004). Briefly, three images were captured with a CCD camera
for each metaphase: (1) a reverse DAPI image, which allows for chromosome
identification and subsequent karyotyping; (2) a test/ FITC image, showing telomeric and
centromeric probe signals; and (3) a reference/ propidium iodide image that allows for
visualization of the chromosome body. Fluorescent intensities obtained from the “test”
and “reference” images were used for calculating the ratio profiles of relative telomere
intensity for each chromosome arm. Overlapping telomeres or telomeres that were in
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close proximity were excluded from the analysis. For each person the intensity values
were averaged over 20 homologs from 10 euploid cells and 20 homologs from trisomic
cells (30 homologs for chromosome 21). A representative metaphase stained with
telomeric probe and centromeric probe for chromosome 2 with DAPI/PI counterstain is
shown in Figure 9.

Cen-2 intensities of all individuals were standardized to a value of 4, and the
respective telomere lengths for each person adjusted proportionally. All statistical
analyses were performed using the R statistical software program.
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(a)

(b)

(c)

(d)

(e)

Figure 9: Representative images showing FISH-based quantification of
chromosome-specific telomere intensity. Image (a) is a metaphase spread stained with
DAPI, which allows for chromosome identification as shown in a reverse DAPI image
(d). Image (b) shows the FITC-labeled PNA telomeric signals and the PNA centromeric
signal for chromosome 2 (test image). Frame (c) shows this same metaphase as it appears
with a PI-stain (reference image). For each chromosome, CGH software transformed the
intensities of telomere signals into ratio profiles averaged over the 20 (or 30) homologs.
These ratios were based on the florescence intensities of the test and reference images. As
seen in (e), telomeres of chromosome X, as identified by the inverted DAPI banding
pattern, showed a short arm telomere relative fluorescence unit (RFU) value of 4.25,
while the long arm telomere value was 5.00. Note that signal intensities between the
replicate sister chromatids of each homolog were very similar.
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Results

Chromosome-specific telomere length assays were performed on lymphocyte
samples obtained from 24 individuals with mosaicism for trisomy 21, including 12 males
and 12 females. These study participants ranged in age from 3 weeks old to 28 years old,
with a median age of 3.5 years old. The age, gender and percentage of trisomy 21 cells
for each proband are given in Table 6. The distribution of the percentage of trisomic cells
and the age of all study subjects are shown in Figure 10.

Overall telomere length in euploid and trisomic cells
Estimates of the overall telomere intensity in each individual were obtained by
averaging the intensity values of all chromosomes, except chromosome Y (which was
excluded from the analysis since the females would not have a correlate chromosome).
This analysis showed no significant correlation between overall telomere intensity values
and the percentage of trisomic cells, which was log transformed values present in the
probands (Pearson correlation, r = -0.15, p-value = 0.485). In addition, no correlation
between overall telomere intensity values and age was observed in the study cohort,
which was comprised of predominantly young individuals (Pearson correlation, r = 0.117, p-value = 0.587) as shown in Figure 11a and 11b.
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Table 6: Age, gender and percentage of trisomy 21 cells of 24 study subjects

Case

Age

Gender

Percentage of trisomy 21 cells

1

0.4

F

24.9

2

4.0

F

19.0

3

0.1

M

50.5

4

12.0

F

26.5

5

3.0

M

23.8

6

0.3

M

48.0

7

2.0

F

9.4

8

28.0

F

90.5

9

5.0

M

12.0

10

25.0

M

8.4

11

14.0

F

10.3

12

7.0

F

91.6

13

3.0

M

29.5

14

11.0

F

17.6

15

0.9

M

62.0

16

4.0

M

10.8

17

0.3

F

56.8

18

0.5

M

10.9

19

11.0

M

6.55

20

21.0

F

92.7

21

2.5

F

43.0

22

3.0

F

23.2

23

18.0

M

11.0

24

2.9

M

11.7
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(a)

Distribution of trisomic percentage of 24 study subjetcs
12

Frequency

10
8
6
4
2
0
0-20

21-40

41-60
1

61-80

81-100

Trisomy 21 cells (%)

(b)

Frequency

Distribution of age of 24 study subjetcs
16
14
12
10
8
6
4
2
0
0-5

5-10

11-15 1 16-20

21-25

26-30

Age (years)

Figure 10: Distribution of the percentage of cells having trisomy 21 and age for the
24 study subjects. Note the skewing of distribution of trisomic cells toward low levels
(less than 20%) (a), and the skewing of the study participants’ age toward very young
individuals (less than 5 year old) (b).
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To test the primary hypothesis of this study, the overall telomere intensity values
between euploid and trisomic cells “within a person” were compared. Telomere
intensities for the short arm of the 23 different chromosomes (1-22 and X) in females and
24 different chromosomes (1-22, X and Y) in males were compared between the two cell
types using a paired t-test. Analyses were performed in the same manner for long arm of
the chromosome. A Bonferroni correction for multiple comparisons was applied for these
tests [the p-value was set at < 0.001 (i.e., 0.05/46 and 0.05/48)]. The mean, standard
deviation, mean of the differences and p-values for these individual-specific comparisons
are summarized in Table 7. A significant difference between telomere intensity values
present in euploid compared to trisomic cells was observed for 7 individuals for the short
arms of chromosomes and in 13 individuals for the long arms of chromosomes. A total of
7 individuals had significantly different values for both their short arms and long arms.
For each of these cases, there was consistency in the directionality of the observed
differences (i.e., shorter in the trisomic cells for both long arm/short arm or longer in the
trisomic cells for both long arm/short arms). No clear ascertainment pattern was observed
for the probands who had shorter telomeres in their trisomic cells versus those who had
longer telomeres in their trisomic cells (not apparently related to age or the proportion of
trisomic cells).
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6.0
5.5
5.0
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4.0
3.5
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2.5
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1.5
1.0
0.5
0.0

Mean telomere intensity and
percentage of trisomy 21 cells

(b)

Mean telomere intensity and age
6.0
5.5

Mean telomere intensity

Mean telomere intensity

(a)

5.0
4.5
4.0
3.5
3.0
2.5
2.0

r = - 0.227, p = 0.587

1.5

r = - 0.15, p = 0.485
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Figure 11: Overall mean telomere intensity compared to (a) the probands’
percentage of cells with trisomy 21 and (b) the proband’s age. Each data point
represents an individual (○). No significant correlation was observed for the trisomic
percentage (Pearson correlation, r = -0.15, p-value = 0.485) or age (Pearson correlation, r
= -0.117, p-value = 0.587).
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Table 7: Telomere intensity values in euploid compared to trisomic cells obtained from lymphocytes of individuals having mosaicism for
trisomy 21.
Short arm

Age
Euploid cells
(years)

Trisomy 21 cells

Long arm

Mean of the differences

Mean

SD

Mean

SD

(e-t )

0.1

2.883

0.544

3.188

0.809

-0.305

0.3

2.780

0.519

2.223

0.361

0.556

0.3

4.916

1.149

4.349

1.068

0.568

0.4

3.630

0.846

3.851

0.937

0.5

4.883

1.287

4.589

1.147

0.9

4.206

1.015

3.883

2.0

2.848

0.792

3.376

2.5

2.774

0.544

2.9

4.297

3.0

2.000

3.0
3.0

p-value

Euploid cells

Trisomy 21 cells

Mean of the difference

p-value

Mean

SD

Mean

SD

(e-t)

0.027

2.789

0.416

2.933

0.548

-0.144

0.095

<0.0005

2.568

0.502

2.148

0.405

0.420

<0.0005

0.006

4.526

1.097

4.013

0.939

0.513

0.003

-0.221

0.137

3.707

0.883

3.397

0.774

0.311

0.957

0.294

0.092

4.443

0.860

4.551

0.923

-0.108

0.490

1.004

0.322

0.027

4.008

0.816

3.610

0.838

0.399

0.004

0.829

-0.529

<0.0005

2.469

0.495

3.152

0.745

-0.683

<0.0005

2.100

0.647

0.674

<0.0005

2.489

0.419

1.739

0.237

0.750

<0.0005

1.019

4.485

0.979

-0.189

0.078

3.993

0.740

3.954

1

0.009

0.956

0.352

2.155

0.277

-0.154

0.017

2.021

0.272

2.249

0.392

-0.228

0.0004

6.587

1.374

5.856

1.397

0.731

0.058

6.166

1.379

5.608

1.256

0.558

0.076

3.559

0.504

2.666

0.482

0.892

<0.0005

3.227

0.556

2.606

0.568

0.622

<0.0005

4.0

2.917

0.443

2.580

0.412

0.337

0.001

2.857

0.369

2.472

0.361

0.385

<0.0005

4.0

3.157

0.733

2.764

0.472

0.394

0.006

3.229

0.705

2.565

0.435

0.664

<0.0005

5.0

4.256

1.009

4.485

0.979

-0.228

0.034

3.956

0.733

3.984

1

-0.0282

0.870

7.0

2.363

0.586

2.917

0.523

-0.554

<0.0005

2.291

0.389

2.678

0.387

-0.389

<0.0005

11.0

3.426

0.811

2.737

0.681

0.690

<0.0005

3.296

0.688

2.581

0.550

0.716

<0.0005

11.0

2.533

0.527

2.879

0.741

-0.345

0.001

2.410

0.592

2.844

0.832

-0.434

0.036

12.0

2.759

0.432

3.575

0.597

-0.816

<0.0005

2.646

0.490

3.415

0.497

-0.769

<0.0005

14.0

2.295

0.589

2.197

0.337

0.098

0.249

2.019

0.352

2.090

0.390

-0.070

0.332

18.0

2.948

0.750

3.360

1.819

-0.412

0.052

2.575

0.492

2.942

0.625

-0.368

0.0004

21.0

2.819

0.621

3.166

0.702

-0.347

0.029

2.779

0.740

2.983

0.493

-0.204

0.210

25.0

2.887

0.909

2.795

0.568

0.091

0.606

2.577

0.524

2.846

0.614

-0.269

0.0003

28.0

2.266

0.412

2.730

0.565

-0.464

0.001

2.102

0.324

2.552

0.488

-0.450

<0.0005
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Chromosome-specific differences in telomere length
The telomere intensity values of each of the autosomal and sex chromosomal arms of all
individuals (n = 24 for chromosomes 1-22 and X; n = 12 for chromosome Y) were visualized
using boxplots of the raw data for euploid and trisomic cells (Figure 12). In this figure, telomere
intensities were not equal among all chromosome arms. The shortest telomeres were found on 9q
for both trisomic and euploid cells, with 1p, 2q, 4p, 16q, 17p, 17q, 19p and 22q also tending to
have relatively short telomeres. The longest telomeres were found on 3p for both trisomic and
euploid cells, with the Y chromosome also tending to have longer telomeres in the males
evaluated.

A striking similarity of the telomere length profiles of the euploid and trisomic cells was
also observed (Figure 13a). The difference in telomeric values in the euploid compared to
trisomic cells resulted in positive values (shorter in trisomic cells) for 26 chromosomal arms and
negative values (longer in trisomic cells) for 21 chromosomal arms (Figure 13b). However, the
majority of these values were not significant using a paired t-test, except for the difference for
2q, and 6q (Table 8). However, if one applies a Bonferroni correction for multiple tests (48
tests); none of the observed difference values reach statistical significance.
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Figure 12: Boxplot distribution of chromosome-specific telomere lengths in euploid and trisomic cells of all study
subjects (n=24). The data for the individual chromosomes in euploid cells (light blue = short arm, pink= long arm) and
trisomic cells (dark blue =short arm, red = long arm) is shown by the minimum (lower bar), 25th percentile (lower box
boundary), median (line), 75th percentile (upper box boundary) and maximum (upper bar).
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Figure 13: Mean telomere lengths in euploid and trisomic cells of all study subjects (n=24). (a) The data from individual
chromosome arms in euploid cells (gray) and trisomic cells (black) reveal a nearly parallel course for all chromosomes. (b) The
difference (euploid-trisomic) in telomere intensity values are shown for each chromosome.
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Table 8: Chromosome-specific telomere lengths in euploid and trisomy 21 cells obtained from lymphocytes of individuals with mosaicism for
Down syndrome (n=24)
Short arm
Chromosome

Eup cells

Tri21cells

Mean

SD

Mean

SD

1

2.381

0.471

2.314

0.431

2

3.474

0.682

3.405

3

4.300

0.899

4.391

4

2.471

0.380

5

3.166

0.589

6

3.448

7
8

Long arm

Mean difference (e-t)

p-value

Eup cells

Tri 21 cells

Mean

SD

Mean

SD

Mean difference (e-t)

p-value

0.067

0.532

3.554

0.7250

3.657

0.687

-0.103

0.562

0.838

0.068

0.683

2.392

0.376

2.160

0.463

0.231

0.044

0.920

-0.090

0.635

3.463

0.685

3.303

0.623

0.160

0.327

2.593

0.423

-0.122

0.317

3.753

0.649

3.767

0.736

-0.013

0.935

2.972

0.579

0.194

0.197

3.081

0.485

3.006

0.506

0.074

0.538

0.553

3.658

0.802

-0.211

0.181

3.518

0.707

3.220

0.641

0.299

0.049

2.885

0.359

2.760

0.569

0.125

0.238

3.331

0.615

3.132

0.512

0.199

0.232

3.418

0.554

3.608

0.733

-0.190

0.198

2.798

0.499

2.672

0.556

0.126

0.282

9

4.051

0.697

3.868

0.669

0.183

0.285

2.303

0.444

2.214

0.413

0.090

0.310

10

3.585

0.572

3.698

0.792

-0.113

0.441

2.856

0.512

2.845

0.590

0.011

0.931

11

2.855

0.472

2.843

0.489

0.012

0.912

3.454

0.669

3.685

0.814

-0.231

0.172

12

3.146

0.636

3.081

0.633

0.065

0.702

2.988

0.509

3.031

0.528

-0.043

0.752

13

3.371

0.615

3.458

0.821

-0.087

0.574

3.467

0.619

3.509

0.859

-0.041

0.818

14

3.233

0.741

3.284

0.782

-0.050

0.769

3.057

0.500

2.972

0.589

0.085

0.568

15

3.242

0.964

3.166

0.603

0.075

0.743

3.469

0.659

3.550

0.773

-0.081

0.699

16

2.621

0.471

2.568

0.457

0.053

0.628

2.562

0.462

2.628

0.519

-0.066

0.578

17

2.806

0.651

2.748

0.611

0.057

0.738

2.612

0.396

2.547

0.565

0.064

0.611

18

3.810

0.684

3.691

0.799

0.120

0.503

3.768

0.579

3.785

0.745

-0.017

0.923

19

2.513

0.441

2.550

0.555

-0.036

0.784

2.988

0.483

3.293

0.991

-0.304

0.188

20

3.313

0.480

3.283

0.667

0.030

0.861

2.704

0.311

2.672

0.470

0.032

0.770

21

3.655

0.829

3.816

1.240

-0.161

0.548

3.012

0.553

2.950

0.649

0.063

0.718

22

3.851

1.306

3.660

1.120

0.191

0.465

2.490

0.430

2.560

0.517

-0.070

0.475

X

3.600

0.851

3.420

0.681

0.180

0.352

3.277

0.705

3.281

0.844

-0.005

0.982

Y

4.269

0.473

4.520

1.345

-0.251

0.470

3.387

0.710

3.758

0.737

-0.371

0.124
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Discussion

Telomere shortening has been previously observed in older individuals with
Down syndrome, compared to normal age-matched controls, using terminal restriction
fragment (TRF) methodology (Vaziri et al., 1993). The TRF assay is one of the first
techniques used to assess telomere length. Based on the fact that that telomeres lack
cleavage sites for restriction enzymes, the TRF assay is implemented by cutting
genomic DNA using a common 4 base-cutter restriction enzyme, followed by gel
electrophoresis and hybridization to a probe with telomere specific sequence, to
obtain an average (pooled over all chromosomes) telomere length based on the size
parameters of the resulting DNA smear. However, if a subset of chromosomes has
short telomeres, or possibly have elongated telomeres, this information could be
missed using the TRF assay. Therefore, in this study, we elected to investigate the
length of telomere repeats using a chromosome-specific assay. Also, by studying
individual chromosome arms in people who have mosaicism for trisomy 21, we were
able to measure telomere lengths in normal and trisomic cells obtained from the same
individual, thereby controlling for the potentially confounding effects of heritable
variation in telomere lengths and different environmental exposures between people.

This is the first study to use quantitative FISH methodology to measure
chromosome-specific telomere length profiles of trisomic and euploid cells. However,
this chromosome-specific assay has been previously shown to be a reliable measure of
telomere length in studies completed on a variety of cell types from different
individuals (Lansdorp et al., 1996; Martens et al., 1998; Graakjaer et al., 2003).
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Specifically, we have shown that the overall average of telomere length estimates
obtained from our adaptation of the quantitative FISH assay correlate with the
estimates obtained from the “gold standard” TRF assay (Leach et al., 2004).

Of twenty-four subjects evaluated in this current study, we observed a weak
negative correlation between telomere intensity values and the percentage of trisomic
cells present in the probands. However, our observation failed to show a significant
correlation between percentage of trisomy 21 cell and telomere length. This
observation could be attributable to the small sample size. In addition, given that the
individuals with mosaicism who were evaluated in this project had a skewing of their
distribution of trisomic cells toward low levels (less than 20%), as shown in Figure
10a, it is difficult to conclude that dosage of trisomy 21 cells has no impact on
telomere length. The lack of a clear effect of the proportion of trisomic cells on
telomere length could reflect the low percentage of trisomic cells in these individuals,
who also showed fewer other phenotypic traits seen in people with Down syndrome,
suggesting they had a lower “threshold” of imbalance.

We also observed a weak, non-significant negative correlation between
telomere intensity and age. However, the skewing of the study participants’ age
toward very young individuals (less than 5 year old) is a possible explanation for this
observation. Therefore, since most of study subjects were very young, we cannot
conclude that in general, age has no effect on telomere length in individuals with
mosaicism for Down syndrome. However, this study is the first to show that the
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presence of a trisomic complement in young individuals has a minimal impact on
telomere length.

While no generalized effect of trisomy 21 was observed, differences in overall
telomere intensity between euploid and trisomic cells “within a person” were detected
for a subset of people. Approximately 50% of all individuals studied had telomere
intensity values in euploid cells that were brighter than those in the trisomic cells for
both arms of their chromosomes. However, significant differences were found in only
16.7% for short arms and 25% for the long arm. Unexpectedly, the young adults in
this study (18 to 28 years old) tended to have longer telomeres in their trisomic cells
longer compared to their euploid cells.

These observations suggest that the telomere length dynamics in young
individuals having low levels of trisomic cells are not clearly different from those of
young people having normal chromosomal complements, the latter of whom have
been shown to have the greatest decrease in their telomere length during the first years
of life, with little additional attrition occurring until they reach middle age (Zeichner
et al., 1999).

We found that telomere lengths were not equally distributed among all
chromosome arms. We also observed that while each person has his/her own specific
telomere length profile; there was a common profile of telomere length shared
between different individuals. This observation is also consistent with results of
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previous reports in people with normal chromosomal complements (Graakjaer et al,
2003, Mayer et al., 2006).

The finding that both trisomic and euploid cells had strikingly similar
chromosome-specific telomere length profiles (Table 8 and Figure 13a) implies that:
(1) dosage of trisomy 21 cells has a minimal impact on telomere lengths in this young
population; and (2) the impact, if any, tends to be generalized for all chromosomes.

In summary, the results of this study failed to detect a clear influence of a
trisomy 21 complement in telomere length in young children and young adults.
However, this conclusion does not seem to apply to older people having trisomy 21.
Telomeres in euploid and trisomic cells may be subjected to different regulatory
control processes and such processes may be acquired later in life. In addition,
sensitivities to mutations that are accumulated over time, which could result in
different in telomere attrition rates, may be different between euploid and trisomic
cells. Furthermore, the cell cycle in people having trisomy 21 has been shown to be
shorter than that of normal people (Leonard and Merz, 1983). Given this observation,
it is feasible that the telomeric attrition observed in older individuals having Down
syndrome simply reflects the fact that their cells have completed more rounds of
replication. The shortening of the cell cycle may also explain, at least in part, the
premature aging phenotype associated with Down syndrome since trisomic
individuals complete more cell cycles in a smaller amount of time. Clearly, additional
studies should be carried out in extended populations with individuals from older
ages. In addition, it would be very interesting to perform a longitudinal study in this
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young population, to measure their rate of telomere shortening in trisomic and euploid
cells compared to that of age-matched controls having a normal complement.
Collectively, further studies of telomere length variation in people having mosaicism
could provide insight about the association between telomere attrition and the
premature aging phenotype in Down syndrome.
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Chapter 4

Frequency of chromosomal instability and chromosome-specific telomere length
profiles in individuals with mosaicism for Down syndrome

Introduction

Acquired chromosomal changes have been associated with the development of
several diseases including, but not limited to, solid tumors [such as malignant glioma
(Lindström et al., 1991), prostate cancer (Zitzelsberger et al., 1994), renal cell
carcinoma (Kuroda et al., 2010), malignant melanoma (Balaban et al., 1986)];
hematological disorders [such as leukemia and lymphoma (Kaneko et al.,1982, Clare
et al., 1982, Hagemeijer et al., 1981; Wisniewski and Hirschhorn,1983)]; and
neurological disorders [such as Alzheimer disease (Migliore et al., 1997; Petrozzi et
al., 2002; Zekanowski and Wojda, 2009) and Parkinson disease (Petrozzi et al., 2002;
Migliore et al., 2002; reviewed in Migliore et al., 2011)]. Several investigators have
shown the frequencies of acquired chromosomal abnormalities involving the sex
chromosomes to be increased in cultured lymphocytes from healthy older individuals
(Jacobs et al, 1961; Jacob et al., 1963; Fitzgerald and McEwan, 1977; Martin et al,
1980; Guttenbach et al, 1995; Richard et al, 1994; Catalan et al, 2000), but there is a
paucity of information available regarding the frequency of acquired autosomal
abnormalities and their clinical consequences. Furthermore, while sex chromosome
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loss has been clearly shown to be correlated with age (Bolognesi et al., 1999; Bonassi
et al., 2001), the influence of age on acquired autosomal aneuploidy is not well
established. Evidence for a relationship between aging and an increased frequency of
acquired chromosomal instability comes from studies of individuals having premature
aging syndromes, such as Werner syndrome. Cells from individuals having Werner
syndrome have shown a higher incidence of chromosomal abnormalities than cells
from normal controls (Crabbe et al., 2007; Ariyoshi et al., 2007). These studies also
showed a relationship between telomere dysfunction and acquired chromosome
abnormalities (Crabbe et al., 2007; Ariyoshi et al., 2007), which is a finding that
supports the previous hypotheses of Barbara McClintock (McClintock, 1941). Aviv
and Aviv (1998) proposed that erosion of the telomere leads to genomic instability. At
the chromosomal level, the resultant abnormalities may give rise to chromosome
fragments lacking a centromere (acentric fragments), which would subsequently not
be pulled toward the daughter nuclei at the time of nuclear division and would either
randomly segregate to the nuclei of daughter cells or be excluded into a small
cytological structure called a micronucleus/micronuclei (MN).

It is well documented that people with Down syndrome age prematurely, as
they show signs of degenerative changes in their physical appearance, including
premature graying and loss of hair, age-related visual and hearing loss, skin atrophy
and neuropathologic features identical to those observed in people having Alzheimer
disease (Potter, 1991; Esbensen, 2010). However, little is known about the frequency
of acquired chromosome abnormalities in people having Down syndrome.
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In addition to the standard G-band karyotyping, the cytokinesis-blocked
micronucleus (CBMN) assay is one of the preferred methods for assessing acquired
DNA damage at the chromosome level (Fenech et al., 2003). It allows for the
measurement of acquired whole chromosomal loss and/or chromosomal structural
abnormalities (i.e., acentric fragments; dicentrics, etc.), with the aberrant chromatin
being excluded into MN. Different mechanisms may be involved in the formation of
MN, including (but not limited to): 1) misrepaired or unrepaired DNA double-strand
breaks resulting in acentric chromosome fragments; 2) hypomethylation of
centromeric and pericentromeric repeat sequences leading to malsegregation of
chromosomes and subsequent loss; and 3) mutations leading to defects in
kinetochores or microtubules, defects in mitotic spindle assembly, mitosis check point
genes; and/or abnormal centrosome amplification. A strong correlation between
chromosomal aberrations, as assessed using the gold standard of metaphase
chromosome studies and MN formation has been shown (Ramalho et al., 1988). The
CBMN assay also allows for measurement of other biological markers which appear
as distinctive cytological structures, including nuclear buds (NBUD), which are
thought to be biomarkers of elimination of amplified DNA and/or DNA repair
complexes, and nucleoplasmic bridges (NPB), which are thought to be biomarkers of
DNA misrepaired and/or telomere end fusions (Fenech et al., 2011).

NPB are thought to originate primarily from dicentric chromosomes that are
pulled to opposite poles of the cell during anaphase. In turn, dicentric chromosomes
are thought to arise from misrepair of chromosome breaks or telomere end fusions. In
addition, defects in protein complexes involved in sister chromatid separation during
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anaphase may result in NPB formation. NBUD are thought to occur as a means for
elimination of amplified DNA, but may also be present as a remnant of NPB breakage
(Fenech et al., 2011).

MN frequencies have not been extensively studied in individuals with Down
syndrome (Table 9). Investigators who evaluated buccal cells showed a significant
increase in MN frequencies in individuals with Down syndrome compared to normal
healthy controls (Thomas et al., 2008; Ferreira et al., 2009). However, the studies
completed in lymphocytes were discrepant, with one group of investigators finding a
decrease in MN frequencies in people having Down syndrome (Scarfi et al., 1990),
while the other group saw no significant difference in MN frequencies for people with
Down syndrome compared to age-matched controls (Maluf and Erdtmann, 2001).
Similar discrepancies have been observed when comparing younger people having
Down syndrome to older trisomic individuals, with older subjects tending to have a
higher frequency of spontaneous MN than younger individuals for buccal cells
(Ferreira et al., 2009), but not lymphocytes. However, MN frequencies in older
individuals with Down syndrome have been noted to be higher than those observed in
younger individuals with Down syndrome when their lymphocytes were treated with
mitomycin-C (MMC), which is a DNA cross-linking agent (Scarfi et al., 1990). In
addition, individuals with Down syndrome appeared to be more sensitive to MMC, as
their MMC-induced MN frequency was higher than healthy age-matched controls.
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Table 9: Summary of previous studies assessing MN frequencies in individuals with Down syndrome

Individuals with Down syndrome
Cell type

Older group

Normal healthy controls

Younger group

Older group

Reference

Younger group

Age†(years)

n

MN (%)

Age†(years)

n

MN (%)

Age†(years)

n

MN (%)

Age†(years)

n

MN (%)

Lymphocytes*

37-55, 44.7±3.8

4

0.86±0.1

9-16, 13.0±1.7

3

0.64±0.06

41-54, 45.8±2

6

1.39±0.11

21-33, 27.6±1.5

8

1.02±0.1

Scarfi et al., 1990

Lymphocytes

-

-

-

0.7±1.8

30

10.17±3.64

-

-

-

3.5±4.9

30

9.3±3.1

Maluf et al, 2001

Buccal cells

-

-

-

5-20, 10.4±5.6

21

0.25**

64-75, 67.1±2.6

31

0.14**

18-26, 22.5±2.2

30

0.03**

Thomas et al.,2008

Buccal cells

≥21,30.8±.4

10

1.00**

<10, 5.5±2.6

10

0.45**

≥21, 31.6±8.8

10

0.25**

<10, 5.7±3.2

10

0.2**

Ferreira et al., 2009

10

**

<20, 14.1±3.5
†

0.55

<20, 13.9±3

10

0.15

**

range, mean  S.D., *Overall MN frequency in spontaneous and mitomycin-C (MMC)-induced MN, ** approximated percentage from published histograms
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Clearly, there is a lack of consensus regarding the influence, if any, that a trisomy
21 complement may have on the propensity for a cell to acquire chromosomal instability.
Furthermore, it is not known if the premature aging present in people with trisomy 21 is
associated with an increased frequency of acquired chromosomal abnormalities. One
potential mitigating factor in the interpretation of the previous data is that the observed
difference in response between people having Down syndrome could reflect differences
in their genetic make-up (genes involved in check points, DNA repair, etc), as well as
differences in environmental exposures. Therefore, in this study, we used the CBMN
assay in combination with interphase FISH technology to determine the frequency of MN
in isogenic trisomic compared to euploid cells obtained from older individuals who were
described as having “mosaicism” for trisomy 21. In addition, to determine if the
chromosomal content of the MN and NBUDs had a non-random pattern, we used
Spectral Karyotyping (SKY) technology. To the best of our knowledge, this is the first
study to determine the chromosomal content of MN (using SKY) from the cells of
individuals having Down syndrome.
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Materials and Methods

Study Participants
Lymphoblast cell lines from 8 individuals with mosaic Down syndrome were
ascertained through collaboration with Dr. Edmund Jenkins, who has amassed a
collection of lymphoblast cell lines from individuals who were seen through the New
York State Developmental Disability Service System (Table 10). Upon receipt in our lab,
the cells were thawed and established in culture for at least one week to ensure that the
cells demonstrated growth.

Cell Cultures
Upon the sample arrival, frozen lymphoblast cell lines were quickly warmed to
37oC, washed twice in sterile 1XPBS and established in culture using a lymphoblast
media (RPMI 1640) containing 10% FBS and antibiotic (100 U of penicillin and 100 µg
of streptomycin). Cell cultures were maintained at 37oC, in 5% CO2 until they
demonstrated adequate growth. At that time the cell solutions were sub-cultured to
encourage log growth of the cells, with the harvest occurring 24 hours following subculture initiation. Approximately 30 minutes before harvesting, colcemid was added to
the cultures to enrich the cultures for cells at metaphase. Chromosomes were harvested
using standard procedures (Moorhead, et al., 1960).
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CBMN and FISH Assays
After successful establishment in culture, cytochalasin B (Cyt-B) was added to a
final concentration of 3µg/ml, 44 hours after sub-culturing. Cyt-B, which inhibits
cytokinesis by blocking microfilaments, captures cells at the telophase portion of the cell
cycle, thereby preventing the cytoplasm from dividing and causing the resultant cell to
appear binucleated. Twenty-eight hours after the addition of Cyt-B, lymphoblast cultures
were harvested as described previously (Leach and Jackson-Cook, 2001). Cell pellets
were dropped onto slides. The slides were then placed on a hot plate at 60C for 1 hour,
followed by aging at room temperature for 4 days. FISH was performed using probes
specific for chromosome 21 (test probe) and chromosome 13 (control probe). The test
probe used was one that is localized to 21q22.13-21q22.2
(D21S259\D21S341\D21S1432) (Abbott, IL). The control probe was specific for band
13q14 (RB1 locus) (Abbott, IL) and served as an internal control for hybridization
efficiency. These probes were hybridized onto cytokinesis-blocked cells to determine
their trisomic versus euploid status. Briefly, prior to hybridization the slides were
dehydrated in a cold ethanol (series of 70%, 85% and 100% ethanol). Following
dehydration, the slides were air-dried. A total of 10μl of the 13/21 probe mixture was
added to appropriate hybridization areas on the slides. The target chromatin and probes
were then co-denatured at 73°C for 2 minutes and hybridized in a pre-warmed,
humidified chamber at 37ºC for 4-16 hours. Upon completion of hybridization, the excess
and non-specifically bound probes were removed by washing (0.4X SSC/0.3%NP-40
solution at 72°C for 2 minutes, followed by 2X SSC/0.1% NP-40 wash solution for 1
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minute). The chromatin in the binucleates was visualized by staining with a
DAPI/antifade solution (Abbort, IL). Probe signals were visualized using a Zeiss Axiskop
equipped with single (spectrum Orange, Spectrum Green) and triple band pass filters. For
each individual, a total of 1000 cells were randomly scored to determine the percentage
of trisomic cells present. In addition, a total of 500 binucleated cells were randomly
scored for frequencies of MN, NPB and NBUD in trisomy 21 compared to euploid cells.
The criteria for recognition of binucleated cells, MN, NPB and NBUD followed the
guidelines by Fenech, et al. (2003). Representative images were documented using a
Cytovision Imaging system from Applied Imaging.

SKY analysis of micronuclei
Slides were aged at room temperature for 4 days prior to the SKY experiment.
SKY was performed according to the manufacturer’s protocol (Applied Spectral Imaging,
CA) as adapted by Leach and Jackson-Cook (2001). Briefly, slides were denatured in a
70% formamide/2XSSC solution (pH 7.0) at 73˚C for 2 minutes. Following denaturation,
the slides were briefly rinsed in cold water and then dehydrated in an ethanol series (70%,
85% and 100% for 2 minutes each at room temperature). The SKY probe (Applied
Spectral Imaging, CA) was denatured at 75˚C for 10 minutes and suppression hybridized
at 37˚C for 60 minutes to bind repetitive sequences. After suppression hybridization, the
denatured probe was added to the denatured slides, hybridizion occurring in a humidified
chamber and at 37˚C for approximately 44 hours. At the completion of hybridization, the
excess and non-specifically bound probe was removed by washing (using a
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0.4xSSC/0.3%NP-40 solution at 73˚C for 2 minutes, followed by a one minute wash at
room temperature in a 2xSSC/0.1%NP-40). Indirectly labeled probes (biotin and
digoxigenin) were detected using buffers with avidin-Cy5, mouse anti-digoxin and goat
anti-mouse conjugated to Cy5.5 (provided by manufacturer). All incubations were for 40
minutes at 37˚C. The binucleates were counterstained with DAPI/antifade (Applied
Spectral Imaging, CA) to allow for their visualization. A total of 100 MN and their
contiguous interphase nuclei were identified per study subject using a Zeiss Axioskop
equipped with a DAPI filter and a custom triple-band pass filter (Chroma, VT). Each MN
(with adjacent interphase cells) was captured with a SpectraCube system (Applied
Spectral Imaging, CA). The images were processed using the vendor supplied software
(Applied Spectral Imaging, CA), which classifies the information obtained by using an
algorithm that assigns a spectra-specific pseudocolor to all pixels in the image.

Chromosome-Specific Telomere Length Assay
Slides were aged (either at room temperature for 1-2 weeks or by soaking in
2xSSC for 10 minutes) prior to the FISH experiment. Metaphase chromosomes were
hybridized with a telomere-specific FITC-labeled PNA probe following the
manufacturer’s protocol (DakoCytomation, Denmark). In addition, an FITC-labeled
probe that is specific for the pericentromeric region of chromosome 2 was simultaneously
hybridized to the metaphase spreads as a control (and to serve for standardization of
intensity values from cell to cell) (Mayer et al., 2006). Briefly, slides were fixed in cold
Carnoy’s fixative for 1 hour. After air-drying, the slides were rinsed with 1XTBS (Tris-
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Buffered Saline, pH 7.5) for 2 minutes, fixed in 3.7% formaldehyde in 1XTBS for 2
minutes, and then rinsed (twice in 1XTBS for 5 minutes). The slides were then treated in
pre-treatment solution, containing proteinase K, for 10 minutes, rinsed (twice in 1xTBS
for 5 minutes) and dehydrated (using a cold ethanol series [70%, 85% and 100%]). After
air-drying, the a cocktail probe mixture (11µl of FITC-labeled telomere specific probe
and 1 µl of FITC-labeled centromere-2 probe per subject [a half slide area]) was added
to each slide and the probe and metaphase spreads co-denatured in a thermocycler at
80°C for 3 minutes. After hybridization in a dry hybridization chamber at room
temperature for 2 hours, the excess and unbound probes were removed by rinsing (once
in manufacturer provided rinse solution at room temperature for 1 minute, followed by 5
minutes in a manufacturer provided wash solution at 65°C). Following serial dehydration
in a cold ethanol series (70%, 85% and 100%), the slides were air-dried, and then
counterstained with a 5:1 DAPI/propidium iodide solution.

The telomere lengths of each chromosome were assessed using a semiquantitative FISH method (CGH software from Applied Imaging Cytovision System) as
described by Leach et al., (2004). Briefly, three images were captured with a CCD
camera for each metaphase: (1) a reverse DAPI image, which allows for chromosome
identification and subsequent karyotyping; (2) a test/ FITC image, showing telomeric and
centromeric probe signals; and (3) a reference/ propidium iodide image. Fluorescent
intensities obtained from the “test” and “reference” images were used for calculating the
ratio profiles of relative telomere intensity for each chromosome arm. Overlapping
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telomeres or telomeres that were in close proximity were excluded from the analysis. For
each person the intensity values were averaged over 20 homologs from 10 euploid cells,
and 20 homologs (30 homologs for chromosome 21) from trisomic cells.
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Results

Analyses were completed on lymphoblast samples obtained from 8 individuals
who were previously categorized (by Jenkins, et al) as having two cell lines (acquired
mosaicism for trisomy 21 for 5 cases and constitutional mosaicism for 3 cases), as
summarized in Table 10. Prior to our analyses, the percentages of trisomy 21 cells from
all lymphoblast cultures were re-evaluated. A total of 5 individuals had trisomic cells
predominate, while 2 individuals had euploid cells predominate in the current cultures.
Therefore, chromosomal instability frequencies and telomere length values could be
analyzed in either trisomic or euploid cells from these individuals, respectively, but not
both as was initially planned. For one individual both trisomic (10.7%) and euploid
(89.3%) cells were present.

Cellular distribution of chromosome 21 and 13 probe signals
The proportion of binucleated cells having MN, NPB, NBUD (Figure 14), as well
as the total frequency of cytome assay aberrations (MN + NPB + NBUD) was determined
for each case, along with information regarding their dementia status (Table 10). The
results of the FISH scoring were used to categorize the binucleates (with or without
cytome aberrations) into cells having or lacking signals for chromosomes 21 and/or 13.
These categorizations included cells having numerical abnormalities (i.e., hyperdiploidy
and hypodiploidy) and unequal segregation (i.e., nondisjunction) of the chromosomes 21
and 13 into the daughter nuclei and/or cytological structures as summarized in Table 11.
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Hyperdiploidy of chromosome 21and/or 13 was found to be the most frequent cellular
alteration. Chromosome 21 and 13 were not frequently excluded in MN. Of the 430
binucleates scored that had MN, only 11 (2.56%) contained signals having chromatin
from the region targeted by the probe for chromosome 21, with only 10 MN (2.33%)
having a signal for the chromosome 13 probe. From these binucleates, “corrective” cells,
which showed the exclusion of chromosome 21 or 13 into MN (possible trisomy rescue)
resulting in a balanced complement for the binucleates, were not frequently seen. The
ratio of the corrective cells to non-corrective cells, the latter of which contained an
imbalance of chromosome 21 or 13 (either hyperdiploidy or hypodiploidy) was 1 to 2.67
and 1 to 9 for chromosomes 21 and 13, respectively. Interestingly, 98 of the 430 cells that
contained MN (23%) had numerical aberrations for chromosomes 13 and/or 21 that were
not included in the MN. In comparison, only 115 of the 3,536 binucleates without MN
(3.3%) had acquired numerical aberrations involving chromosomes 13 and/or 21.
Therefore, even though the cytome aberrations did not reflect all chromosomal anomalies
that were present in the cells, the observation of a MN (or other cytome structures) was a
good indicator that the parent cell had chromosomal instability.
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Table 10: Frequencies of MN, NBUD and NPB observed from CBMN and FISH assays and overall telomere length obtained from 8 individuals
with mosaicism for Down syndrome, according to their age, gender and dementia status.
Age at
Case

sample

% Tri21
Gender

collection

% MN
Current

% NBUD and NPB

Dementia Status

Ascertainment

Tri 21

Eup

Tri 21

Eup

% Total Cytome

Mean telomere

Abnormalities*

intensity value

Tri 21

Eup

Tri 21

Eup

cultures
(years)
25

47.7

M

96.0

97.1

No

11.4

1.0

12.4

(57/500)

(5/500)

(62/500)

8.4

0.4

8.8

(42/500)

(2/500)

(44/500)

7.4

2.2

9.6

26

57.8

M

92.0

93.4

No

27

55.1

F

94.0

98.0

No

(37/500)

(11/500)

(48/500)

28

60.4

M

92.0

97.8

No  dementia

13.4

0.6

14.0

(at age 63)

(67/500)

(3/500)

(70/500)

29

78.1

F

90.0

94.6

Yes

14.0

0.6

14.6

30

48.6

M

78.0

1.0

No

31

57

F

16.0

1.2

MCI  dementia
(at age 59)

(70/500)

32

43.1

F

32

10.7

No

(3/500)

1.97

2.30

1.79

1.77

1.59

(73/500)

7.6

0.6

8.2

(38/500)

(3/500)

(41/500)

13.2

1.0

14.2

(66/500)

(5/500)

(71/500)

34.0

8.0

0.67

34.0

8.7

(17/50)

(36/450)

(3/450)

(17/50)

(39/450)

2.63

1.37

2.96

3.32

MCI = mild cognitive impairment, Tri21= trisomy 21cells, Eup = euploid cells, RFU = relative fluorescent unit, *Total cytome abnormalities determined by the sum of
MN, NBUD and NPB
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(a)

(b)

(c)

Figure 14: Representative images of cytological structures observed in binucleated cells following CBMN and FISH
assays using probes specific for chromosome 21 (red) and chromosome 13 (green). (a) A binucleated cell with a trisomy
21 complement that had a MN containing a signal for chromosome 21, suggesting a “trisomy rescue” corrective event occurred
in the right binucleate to give rise to a euploid cell; (b) a binucleated cell with a trisomy 21 complement that had nuclear buds
containing chromatin from chromosome 21, suggesting that a corrective event (trisomy corrected to euploid complement)
occurred for both daughter cells; and (c) a trisomy 21 binucleated cell with a NPB that does not contain chromatin for the
targeted regions evaluated with these probes.
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Table 11: Segregation of chromosomes 21 and 13 into MN and acquired aneuploidy for chromosomes 21 and 13 in binucleates lacking cytome
abnormalities
BN with MN
Case

MN with 21

MN with 13

BN without MN

MN without 21 or 13
NL

NDJ21

NDJ13

NDJ21,13

Hypo

Hyper

Multiple

1

421

4

2

0

4

6

1

8

3

440

1

1

0

6

8

0

0

3

1

426

1

1

1

2

20

1

1

7

12

0

419

1

2

0

2

6

0

0

0

1

11

0

404

2

1

0

8

11

1

1

0

0

1

2

1

446

1

0

0

3

8

1

52

2

1

2

0

3

1

423

0

0

0

0

6

0

4

36

0

1

1

2

6

1

441

0

2

0

0

1

0

9

311

10

4

8

18

50

8

3421

10

9

1

25

66

4

C

NC

C

NC

Typical

NDJ21

NDJ13

NDJ21,13

Hypo

Hyper

Multiple

25

0

2

0

0

43

0

0

1

5

5

26

0

0

0

0

20

5

1

3

2

27

0

1

0

2

30

0

0

0

28

1

1

1

2

40

1

1

29

0

0

0

0

57

1

30

0

0

0

0

33

31

1

3

0

1

32

1

1

0

Total

3

8

1

C = Corrective, NC = Non-corrective, NDJ = Nondisjunction, Hypo = Hypodiploidy, Hyper = Hyperdiploidy, Multiple = Hypodiploidy and hyperdiploidy

MN with 21
corrective

MN with 21
hyperdiploidy

MN with 21
hypodiploidy

MN without 21
typical

MN without 21 MN without 21 MN without 21 MN without 21 MN without 21
with NDJ 21 with NDJ 21, 13 hyperdiploidy hypodiploidy
multiple
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Telomere length and correlations of telomere length with the frequency of MN,
NBUD and NPB
Figure 15 shows representative images of metaphase chromosomes from an
individual without dementia and an individual with dementia and illustrates the overall
trend that was observed for telomeres having less intensity (shorter) in individuals with
dementia as compared to individuals without dementia.

For these analyses, the individuals studied were categorized into 2 groups: nondemented (n = 5) and demented (n = 3), regardless of their cell types. Age ranges were
43.1-57.8 years old (median = 48.6) and 57-78.1 (median=60.4) for non-demented and
demented groups, respectively. The frequency of cytome abnormalities (MN, NBUD, and
NPB), as well as the overall telomere lengths are shown in Figure 16a and 16b,
respectively. To compare the frequency of cytome abnormalities and the overall telomere
length between the non-demented and demented group, the Mann-Whitney U test was
applied. This statistic involves ranking all the observations, from the smallest to the
largest values regardless the dementia status. A U statistic was then calculated using the
following formula:
U = R - n (n+1), where n = sample size and R = sum of the rank
2

This test was performed using the R statistical software program. We found that
individuals who had dementia had a significantly higher frequency of cytome
abnormalities (10.0±1.7% vs 14.3±0.3%, p-value = 0.036, Mann-Whitney U test). A
regression analysis showed that the observed increased frequency of cytome
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abnormalities significantly co-varied with age (p-value = 0.003), but age effects alone
were not attributable for the observed cytome frequency differences (p-value = 0.59).
Telomere intensity scores between cells from individuals with and without dementia were
also compared. The telomere intensity values of the cells from people with dementia were
significantly lower than those observed in cells from people without dementia (1.58±0.20
vs 2.37±0.54; p-value =0.036, Mann-Whitney U test). A regression analysis showed a
significance co-variance of dementia status and age on telomere intensity values (p-value
= 0.04), but neither attribute independently accounted for a significant portion of the
observed variation (age, p-value = 0.5; dementia, p-value = 0.4). We also observed a
significant negative correlation between telomere length and frequency of MN, NBUD
and NPB (Spearman correlation, r = - 0.785, p-value = 0.028) over all study participants
(Figure 17).
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(a)

(b)

Figure 15: Representative images of metaphase spreads following the chromosome-specific telomere length assay. In
image (a) are metaphase chromosomes from an individual without dementia; with image (b) showing metaphase chromosomes
from an individual with dementia. Note the overall decreased fluorescent intensity of the metaphase chromosomes from the
individual with dementia [most telomeres are not readily visible and less intense than the centromeric control probe] as
compared to the individual without dementia [all telomeres are easily visualized with bright signals that are comparable in
intensity to the signal of the centromeric control probe].
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Mean MN,NBUD,NPB

(a)

Frequency of cytome abnormalities
16.0%
14.0%
12.0%
10.0%
8.0%
6.0%
4.0%
2.0%
0.0%
Dementia -

(b)
Mean telomere intensity

3.5

Dementia +

Mean telomere intensity

3
2.5
2
1.5
1
0.5
0
Dementia -

Dementia +

Figure 16: Frequencies of cytome abnormalities (total MN, NBUD and NPB) and
overall telomere length (signal intensity). Individuals without dementia (n = 5) and
individuals with dementia (n = 3) are shown. The data is presented as the mean and
standard deviation for each group. (a) The frequency of cytome aberrations in individuals
with dementia was significant higher than those observed in individuals without dementia
(p-value = 0.036, Mann-Whitney U test). (b) Telomere lengths (signal intensities) in
individuals with dementia were significant higher than those observed in individuals
without dementia (p-value = 0.036, Mann-Whitney U test).
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Frequency of cytome abnormalities

Relationship between frequency of cytome abnormalities and mean
telomere intensity
16%
14%
12%
10%
8%
6%
4%
2%
0%

r = - 0.785
p-value = 0.028
0

1

2

3

4

Mean telomere intensity

Figure 17: Relationship between frequency of cytome abnormalities and mean
telomere length (signal intensity). A significant negative correlation between telomere
signal intensity (length) and the frequency of cytome abnormalities for individuals
without dementia (white) and individuals with dementia (black) was detected (Spearman
correlation, r = - 0.785, p-value = 0.028). An individual who was later diagnosed as
having dementia is also shown (gray). The data are shown as frequencies/intensities in
trisomic (triangle) and euploid cells (circle). An individual with mosaicism is represented
by □ with their values being the average of the two cell populations.
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Chromosomal contents in MN
The chromatin present in the MN from the trisomic and euploid binucleates was
determined using SKY (Figures 18 and 19). Of the total of 777 MN scored, the majority
(85.71%) contained chromatin from a single chromosome. However, the most frequent
category of MN that was observed contained chromatin from more than one
chromosome, with these MN accounting for 12.4±3.6% of the total number of MN
evaluated from individuals without dementia, and 17.7±0.4% in individuals with
dementia. The frequencies of autosomal and sex chromosome exclusion into micronuclei
were not significantly different between the dementia groups. However, a non-random
pattern of chromosomes present in MN was observed for both groups, with chromatin
from chromosome 16 being present most frequently and chromatin from chromosome 17
being present least frequently. A Mann-Whitney U test with Bonferroni correction for
multiple comparisons was applied for these tests [the p-value was set at < 0.002 (i.e.,
0.05/24)]. The chromosome-specific statistical comparisons between the MN from
individuals with and without dementia are summarized in Table 12.
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(a)

(b)

(c)
Chromosome Y

Figure 18: Representative images of a binucleated cell and micronucleus following the CBMN and SKY assays. (a) A
reverse DAPI image; (b) spectral image; and (c) classified images. In this cell the chromatin content of the micronucleus
originated from a Y chromosome.
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Frequency of chromatin contents in MN
20.0%

Frequency

15.0%
10.0%
Dementia 5.0%
Dementia +
0.0%
-5.0%
Chromosome

Figure 19: Frequency of chromatin contents in MN observed from individuals based on their dementia status. The
proportion of MN containing each of the chromosomes is shown for individuals without dementia (dark gray) and individuals
with dementia (light gray), pooled over all cell types. The data are shown as the mean (histogram) and standard deviation
(error bar). The frequencies of MN that contain chromatin from more than one chromosome are shown in the “mix” category.
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Chromosome-specific telomere length profiles
Chromosome-specific (averaged over the short arm and long arm) telomere
lengths (probe signal intensities) were also determined for the study participants with and
without dementia (Figure 20). Individuals with dementia tended to have shorter telomeres
than the people without dementia for all chromosomes studied. A Mann-Whitney U test
with Bonferroni correction for multiple comparisons was applied for these tests [the pvalue was set at < 0.002 (i.e., 0.05/24)]. None of the observed difference values reach
statistical significance. Chromosomes 16 and 17 were found to have the shortest
telomeres in both the non-demented and dementia group. In this study, chromosome 18
was found to have the longest telomeres in both groups. Statistical comparisons between
the individuals from the non-demented and demented groups are summarized in Table
12. Individuals without dementia appeared to have nearly the same pattern of
chromosome-specific telomere length (Figure 20b).

We were able to measure chromosome-specific telomere lengths of euploid
compared to isogenic trisomic cells in the one individual who had two cell populations
present in their lymphoblast culture (Figure 21). The telomere intensities tended to be
shorter for nearly all chromosomes in the trisomic cells. However, none of the telomeric
values were significantly different between the cell types (Figure 21).
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Chromosome-specific telomere intensity profile

Mean telomere length

(a)
4.00
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00

DementiaDementia+

Chromosome
Chromosome-specific telomere intensity profile
Mean telomere length

(b)
3.00
2.50
2.00
1.50
1.00

DementiaDementia+

0.50
0.00

Chromosome

Figure 20: Chromosome-specific telomere intensity values in individuals without dementia (dark gray) and with
dementia (light gray). The data are represented by the median (histogram) and interquatile range (error bar). Note that all
telomeres of individuals with dementia are shorter compared to those without dementia. (b) Trend lines of the mean of the
telomere intensity values are shown for each chromosome in the individuals without dementia (dark gray) and with dementia.
Note the nearly parallel course of lines between individuals without dementia (dark gray) and individuals with dementia (light
gray).
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Table 12: Summary of statistical analysis for MN content and telomere length
MN Content
Chromosome

Non-demented

Telomere Intensities

Demented

p-value*

Mean

SD

Mean

SD

1

3.4% -)
(Dementia

3.8%

1.1% +)
(Dementia

1.1%

2

1.7%

1.1%

0.8%

0.7%

3

2.7%

1.6%

4.4%

3.3%

4

7.5%

1.8%

7.5%

5

1.8%

1.7%

6

1.3%

7

Non-demented

Demented

p-value*

Mean

SD

Mean

SD

0.55

(Dementia
2.18 -)

0.69

(Dementia
1.56 +)

0.30

0.14

0.27

2.30

0.67

1.51

0.24

0.14

0.39

2.71

0.58

1.74

0.36

0.04

1.2%

1

2.39

0.47

1.40

0.22

0.04

2.8%

0.9%

0.52

2.25

0.57

1.59

0.23

0.14

0.9%

1.4%

1.2%

0.88

2.43

0.64

1.71

0.27

0.07

0.7%

0.6%

1.9%

1.7%

0.38

2.26

0.54

1.46

0.29

0.04

8

7.1%

2.9%

7.7%

4.3%

1

2.39

0.61

1.56

0.32

0.07

9

3.3%

1.7%

4.6%

2.2%

0.39

2.30

0.70

1.63

0.56

0.14

10

2.1%

1.7%

1.8%

1.7%

1

2.40

0.63

1.69

0.19

0.25

11

6.1%

1.6%

3.8%

0.8%

0.07

2.21

0.42

1.50

0.19

0.04

12

6.4%

3.1%

6.3%

3.8%

1

2.18

0.52

1.70

0.15

0.4

13

7.5%

2.4%

4.5%

1.9%

0.14

2.53

0.36

1.65

0.32

0.04

14

8.4%

1.1%

7.7%

2.0%

0.79

2.70

0.73

1.63

0.37

0.07

15

2.1%

2.0%

2.1%

0.9%

1

2.65

0.79

1.59

0.46

0.07

16

11.4%

3.7%

7.9%

4.1%

0.25

1.96

0.40

1.37

0.23

0.07

17

0.0%

0.0%

0.7%

0.6%

0.11

2.05

0.56

1.31

0.26

0.07

18

2.7%

2.1%

2.1%

0.9%

1

2.70

0.70

1.86

0.27

0.14

19

1.4%

1.0%

1.1%

1.2%

0.63

2.17

0.55

1.40

0.22

0.07

20

4.6%

1.7%

6.4%

2.2%

0.39

2.40

0.61

1.52

0.32

0.07

21

2.4%

0.9%

1.5%

0.7%

0.25

2.43

0.75

1.53

0.28

0.07

22

1.0%

0.7%

1.9%

2.3%

0.88

2.26

0.63

1.62

0.40

0.14

X

2.1%

3.2%

2.5%

2.3%

0.79

2.56

0.64

1.79

0.33

0.04

mix

12.4%

3.6%

17.7%

0.4%

0.14

* p-value prior to Bonferroni
correction
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Mean telomere intensity

Chromosome-specific telomere intensity profile in an individual with mosaicism for Down syndrome
5
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0.61

0.87

0.60

0.17

-0.26

0.61

0.69

-0.17

0.52

0.17

0.08

0.70

-0.09

0.34

0

0.87

0.78

0.17

0.69

0.26

0.18

0

0.26

0.09

0.34

0.26

0.80

0.65

0.08

0.16

0.70

0.20

0.72

0.80

0.15

0.5

0.70

NA

0.24

0.32

0.71

0.16

0.22

0.5

NA

mean
difference
p-value

Figure 21: Chromosome-specific telomere intensity profiles in the individual with mosaicism for trisomy 21.
Chromosome-specific telomere length profiles in euploid and trisomic cells obtained from an individual with mosaicism (but
not dementia) are shown. (a) The data represent mean (histogram) and standard deviation (error bar) values. (b) The
comparisons of the mean differences, using a paired t-test, showed no significant differences.
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Discussion

In this study, we originally intended to evaluate the frequency of chromosomal
instability and chromosomal contents of MN between isogenic trisomic and euploid cells
obtained from individuals with mosaicism for Down syndrome. Of eight individuals who
were ascertained for having “mosaicism”, we were only able to obtain both trisomic and
euploid cells for one of these individuals. Of the 8 cases, 5 lymphoblast cultures had
nearly all trisomic cells. This change in the proportion of cells could be due to selection
against the euploid cells that happened either at the time that lymphocytes were
transformed to lymphoblasts (clonal like selection) at the time of freezing/thawing, or
during the lymphoblast culture maintenance (differential growth). It is likely that these
individuals had full trisomy 21 with an “acquired” loss of chromosome 21 that occurred
later in their lives. It has been reported previously that acquired loss of chromosome 21
happens in elderly people with Down syndrome (Percy et al., 1993; Jenkins et al., 1997).
For those 2 individuals who had euploid cells that predominated, they are likely to have
had “constitutional” mosaicism for Down syndrome, with loss of the trisomic line due to
cell culture selection as described above.

Considering the parallel between the increase in MN frequency and Alzheimer
type of dementia (Migliore et al., 2011), one could hypothesize that the increase in MN
frequency could be related to the early development of Alzheimer symptoms in people
having Down syndrome. In this study, we observed significantly higher frequencies of
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chromosomal instability in individuals who had dementia, compared to those without
dementia, which supports the findings of Migliore and colleagues (2011). We also
observed that individuals who had dementia had significantly shorter telomere than those
without dementia, which is in agreement with the previous report by Jenkins and
colleagues (2008) who looked at mean telomere lengths, but not chromosome-specific
telomere lengths. Given that free radicals have been purported to play a role in the
shortening of telomeres (Von Zglinicki, 2000) and that the superoxide dismutase-1 (SOD1) gene is located on chromosome 21, which encodes an enzyme that is responsible for
destroying free radicals, the observation of telomere shortening associated with a trisomic
complement is a bit counter-intuitive. Increased expression of SOD-1 has been
documented in individuals with Down syndrome. However, H2O2, a product of the
catalytic reaction by SOD-1, will break down to a hydroxyl radical (OH-). OH– is highly
toxic, which can result in profound cellular damage (reviewed in Capone, 2001).
Therefore, individuals with Down syndrome are believed to be vulnerable to oxidative
damage to DNA, including telomeres. The imbalance between oxygen free radical
production and scavenging leads to cellular dysfunction, which in turn, has been
postulated to result in elevated genomic instability (Mancuso et al., 2006). In addition, it
has been reported that individuals with Down syndrome have an accelerated decline in
DNA repair capacity with age (Raji and Rao, 1998). This could also contribute to
chromosomal and/or genomic instability in elderly individuals with Down syndrome.

120

In addition to observing generalized trend toward shortened telomeres in the older
group having dementia, we observed that chromosome 16 had the shortest telomeres for
both the demented, as well as the non-demented individuals. While the telomere intensity
values were not significantly different between the two groups, it is of interest to note
whether there might be genes localized near the heterochromatic telomere whose activity
could be altered by telomeric attrition. Two such genes were identified to be of interest.
One of these genes, called partner and localizer for BRCA2 (PALB2), located on
chromosome band 16p12.2 and encodes a protein that stabilizes and anchors the BRCA2
protein to structures within the nucleus. Therefore, PALB2 is essential for allowing the
DNA double-strand break repair functions of BRCA2, which, in turn, prevents cells from
accumulating genetic damage that can trigger genomic/chromosomal instability
(http://omim.org/entry/6103555). Given that MN could be formed as a result of
misrepaired and unrepaired DNA double strand breaks, shortening of the telomere on
chromosome 16 could be a factor contributing to the higher frequency of MN observed in
individuals with Down syndrome when compared to age-matched controls having a
normal complement, the latter of which is a finding reported by Ferreira, et al. (2009).
The CREB binding protein (CREBBP or CBP) gene is another gene that is located on
chromosome 16 (band 16p13.3). The CREBBP gene has been shown to have an essential
role in long term memory formation in mice (Bourtchouladze et al., 2003)
(http://omim.org/entry/600140). Given that shortening of the heterochromatic telomeric
region could alter the chromatin conformation of the distal long arm, thereby potentially
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altering the function of CREBBP gene, this is an interesting gene to consider for future
studies of the progression of dementia in individuals with Down syndrome.

In this study, we found a significant correlation between telomere shortening and
increased frequency of MN, NBUD and NPB. It is thought that excessive telomere
shortening can eventually result in telomere to telomere end fusions and the formation of
dicentric chromosomes via inappropriate assembly of the telomeric protein structures.
Using the CBMN and FISH assays, we found that hyperdiploidy, hypodiploidy and NDJ
were more common alterations than “corrective” changes leading to MN formation for
chromosome 21 and 13. From MN content analysis using SKY, we found that MN
containing more than one chromosome (mix) was seen more frequently than MN
containing a single chromosome. Taken together, one could speculate that telomeric
shortening is leading to an increased frequency of dicentric chromosome formation in
older individuals with Down syndrome and that the dicentric chromosomes may
contribute to the observed increased frequency of chromosomal instability as shown in
Figure 22.

While we found that the overall telomere lengths (inferred from the reduced
intensity of signal for the telomeres) of individuals with dementia were significant shorter
than individuals without dementia, we observed that the telomeres tended to be shorter
across all chromosomes and the patterns of chromosome-specific telomere length were
very similar for both groups. However, further studies of more individuals, including
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individuals with non-mosaic and mosaic Down syndrome, are needed, which ultimately
may help to identify genomic regions of interest and serve to inform investigators of
potential candidate genes for future investigations in the etiology of dementia.
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(a)

Trisomic binucleate
with nondisjunction
of chromosome 21

(b)

Trisomic binucleate
with MN containing
chromosome 21 and 13

Figure 22: Diagram showing link between telomere shortening and chromosomal
instability. Chromosome 21 is shown in red and chromosome 13 is shown in green. The
left side of the diagram shows the replicated chromosomes’ alignment during metaphase.
Dicentric chromosomes, which form from end-to-end fusion as a result of telomeric
shortening, are highlighted with an arrow. The middle of the diagram shows the
chromosomes following the separation of the sister chromatids during anaphase. As the
chromosomes are pulled toward the spindle poles, the tension exerted by spindle fibers
can cause breakage of the dicentric chromosome, which could result in (a)
nondisjunction; or (b) MN formation following anaphase lagging. The right side of the
diagram shows patterns that would result from these abnormal segregation events in cells
evaluated after the CBMN and FISH assays. Note the content of the MN in (b) is
comprised of a combination of chromatin from chromosomes 21 and 13 (mix).
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Chapter 5
Summary, conclusions, and future directions

A. Array-based technology for mosaicism detection.
- It is important that geneticists who are interpreting the results of microarray studies gain
experience in the assessment of cases having mosaicism. Using the default software
analysis setting for copy number calling alone, is not sufficient to recognize individuals
with mosaicism involving a minor cell population that is present in less than 30% of cells
since the software routinely categorizes log2 ratio changes from 0-30% as copy number
neutral findings. By expanding our analysis to include an assessment of the smooth signal
of the log2 ratio, cases having a minor cell population in as few as 15-20% of cells could
be detected. However, FISH remains the “gold standard” for mosaicism detection. In
addition, FISH should be considered for confirmation when low level mosaicism is
suspected and/or to confirm/refute equivocal array-based results.

- Array-based technology has limitations in identifying mosaicism, and is unable to detect
unbalanced structural chromosome rearrangements, and ploidy changes; however, it
shows strengths in its ability to identify previously unrecognized chromosomal
abnormalities. In addition, due to its high resolution compared to the standard G-banding
analysis, array-based technology allows for refinement of breakpoinst of unbalanced
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structural chromosome abnormalities. Using the SNP array, the origin of a segregation
error (meiosis or mitosis, when coupled with an assessment of parental patterns), and
long contiguous stretches of homozygosity (LCSH), the latter of which may be indicative
of isodisomic uniparental disomy (UPD) or loss of heterozygosity (LOH), can be
detected.

- The relative fluorescence intensities obtained from microarray data were positively
correlated with the percentage of trisomic cells determined by the “gold standard” FISH
methodology. Thus, for specimens in which mosaicism is detected, array-based
technology appears to yield reliable estimates of the proportion of cell populations
present

- A further study including more individuals with various levels of mosaicism for trisomy
21 syndrome, mosaicism involving other constitutional chromosome abnormalities, and
multiple clonal cell lines from cancer specimens should be evaluated to assess reliability
and limitations of this assay by laboratories before it is used in a diagnostic setting (i.e.,
the validation should include mosaic cases) .

B. Chromosome-specific telomere length profiles in euploid and trisomic cells from
younger individuals with mosaicism for trisomy 21.
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- A weak, non-significant negative correlation between telomere intensity values and the
percentage of trisomic cells present in the mosaic probands was observed in this study.
The lack of a clear effect of the proportion of trisomy cells could be attributable to the
small sample size, or a skewing of the distribution of trisomic cells in the study
participants toward low levels (less than 20%). Alternatively, the influence of the
trisomic imbalance could be limited to the cellular boundaries, with the euploid cells
showing no influence from the trisomic cells.

- A weak, non-significant negative correlation between telomere intensity and age was
also observed. The lack of an age effect on telomere intensity values in this young study
cohort of individuals having mosaicism (majority of participants were less than 5 years
old) is consistent with expectations from studies of young individuals having euploid
(normal) chromosomal complements.

- Both trisomic and euploid cells had strikingly similar chromosome-specific telomere
length profiles, which imply that the trisomy 21 imbalance has a minimal impact on
telomere lengths in this young population, with any influences that were present tending
to be generalized for all chromosomes. Although no clear generalized effect of trisomy
21 was observed in this young study cohort, case by case differences in overall telomere
intensity between euploid and trisomic cell “within a person” were detected for a subset
of individuals.
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- Telomere lengths were not equally distributed among all chromosome arms, with a
common pattern of telomere length being observed between genetically unrelated
individuals. In addition, the chromosome-specific telomere length profiles in this cohort
tended to parallel the profiles that have been reported in normal populations.

- Further studies should be carried out in extended populations with individuals from
older ages. In addition, a longitudinal study in this young cohort may provide information
regarding a potential differential rate of telomere shortening in trisomic compared to
euploid cells.

C. Frequency of chromosomal instability and chromosome-specific telomere length
profiles in older individuals with Down syndrome with and without dementia.

- Significantly higher frequencies of cytome abnormalities and significantly shorter
telomere lengths were observed in individuals with Down syndrome who had dementia,
compared to those without dementia. In addition, a significant correlation between
telomere shortening and an increased frequency of cytome abnormailties was observed.
Other cellular alterations, such as hyperdiploidy, hypodiploidy, and nondisjuction
(imbalances) were more common than “corrective” changes leading to micronuclei (MN)
formation. Using SKY, MN containing more than one chromosome were noted to arise
more often than MN containing a single chromosome. Taken together, these findings
suggest that telomere shortening may lead to an increased frequency of dicentric
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chromosome formation and that the dicentric interchromosomal abnormalities may be an
intermediate between the observed increased frequency of hyperdiploidy, hypodiploidy,
NDJ, and MN containing more than one chromosome.

- Further studies, especially the CBMN in combination of FISH and SKY, should be
carried out in an extended population of older individuals having mosaicism for trisomy
21 with and without dementia to further clarify the impact of the trisomic imbalance on
the acquisition dementia. In addition, investigations in young and older individuals with
mosaicism for Down syndrome may provide insight about the effects of constitutional
aneuploidy on the frequency of age-related, acquired chromosomal instability.
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